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ABSTRACT

BLOCKADE OF CXCR4 INHIBITS P. GINGIVALIS PERSISTENCE IN VIVO
AND INDUCTION OF PERIODONTAL BONE LOSS
By
Megan L. Me Intosh

18 May 2012

Chronic periodontitis is strongly associated with composition of the oral biofilm
occupying the gingival crevicular aspect of the tooth and its associated root. Some gramnegative, "red complex" bacteria instigate periodontal bone loss in patients, principal
among these Porphyromonas gingivalis. P. gingivaZis is a "late colonizer", indicating not
only its physical location within the oral biofilm, but also the pathogenic dynamic of the
interaction between P. gingivalis and the host innate immunity. Among several other
subversive tactics, P. gingivaZis has been shown to compel receptors vital to the
orchestration of an appropriate immune response to co-associate and consequently signal
in a way that directly benefits the pathogen. Upon interaction with human monocytes and
murine macrophages, P. gingivalis has been shown to induce TLR2 and CXCR4 to co-

v

associate in lipid rafts via its surface fimbriae. The ensuing crosstalk results in a cAMP
dependent, PKA mediated inhibition of NF-KB which in turn leads to a state of mixed
signals. TLR2 attempts to upregulate NF-KB as CXCR4 simultaneously signals to inhibit
TLR2 antimicrobial signaling. Functionally, this was shown in human monocytes and
mouse macrophages to cause downregulation of TNF-a and upregulation oflL-10. Here
we show the interaction between P. gingivalis fimbriae and CXCR4 to have
physiological relevance to the initiation and maintenance of periodontal bone resorption
in a mouse model of infection. Pharmacologic inhibition of the P. gingivalis fimbriaeCXCR4 interaction prevented bone loss as well as halted progression of periodontal
disease instigated prior to treatment in the Baker Model of oral infection. We also found
that systemic administration of the bicyclam CXCR4 inhibitor AMD3100 leads to
enhanced killing of P. gingivalis in a subcutaneous chamber model of infection. The
subcutaneous chamber is an in vivo model system of the microaerophilic environment of
the gingival pocket as well as the influx of dominantly comprised of neutrophils into the
gingival crevice characteristic of chronic periodontitis. It is interesting that we noted that
CXCR4 deficient mice display a similar host inflammatory profile to wild-type mice
treated with AMD3100. However, while most of these mice were protected from P.
gingivalis-mediated bone loss, one of the CXCR4 deficient mice did not demonstrate

protection from alveolar bone loss when chronically infected with P. gingivalis. These
mice also showed a healthier inflammatory profile compared to their infected, untreated
counterparts. Thus, the results below indicate that AMD3100 effectively inhibits
periodontal bone loss due to the ability of the compound to counter P. gingivalis'
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recognition of CXCR4. This provides evidence supporting the importance of this coreceptor in developing therapeutic strategies for treating periodontal disease.
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CHAPTER ONE: INTRODUCTION

Periodontitis is a chronic inflammatory disease with pathophysiological ties to
systemic conditions such as rheumatoid arthritis, heart disease, and diabetes (18, 145)
(273) (143). Periodontal disease is a widespread condition, with over 75% of adults in the
United States demonstrating some stage of periodontal disease (18) and oral care is an
expensive public health endeavor. According to the CDC, in 2010 $108 billion dollars
was spent on dental care in the United States (209).
P. gingivalis has evolved several elegant mechanisms for survival in the oral

biofilm and subversion of the host immunity, among these the release of gingipains
which cleave complement components C3 and C5, degrading the C3 completely.
Gingipain cleavage, however, leaves the C5a anaphylatoxic "a" fragment functionally
intact. P. gingivalis affects the oral biofilm as extensively as the host immune system,
altering both the total bacterial load and composition, even though the pathogen exists as
an extremely small percentage of the total biofilm (97). Due to these behaviours, P.
gingivalis has been termed a "keystone pathogen" meaning that, although it is typically a

minute component of the oral biofilm, P. gingivalis is critical to the shift and consequent
support of the more pathogenic biofilm now thought to be a majour etiological factor of
chronic periodontal disease. The removal of P. gingivalis should cause the pathologic
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oral biofilm to return, albeit gradually, to a commensal state. P. gingivalis infection has
been shown to be indicative of poor prognosis in chronic periodontitis, thus control or
eradication of P. gingivalis is a target therapeutic strategy in periodontal disease (211)
(197). For this reason, we focus on P. gingivalis as our primary target for periodontal
therapy.

Periodontal Disease

Most adult humans demonstrate some degree of gingival or periodontal disease,
with gingivitis being greatly increased in prevalence compared to its more severe cousin,
periodontitis. According to the World Health Organization, periodontal disease is the
major cause of tooth loss in adults over 40 years of age and affects human populations
globally. Although it is less common, severe periodontal disease, defined clinically as 6
millimeters or greater of periodontal pocket attachment loss, affects about 14 percent of
adults aged 45 to 54 (1). The most severe forms of periodontitis can reach rates of 10% to
20% prevalence in disadvantaged populations or those with high instances of
predisposing behaviour (204). Periodontal disease is furthermore associated with an
increase in premature death among adults (245) (244).
The gingivae, periodontal ligament and cementum to which the ligament attaches
hold the tooth in place and this anatomical arrangement is collectively referred to as the
periodontium. (See Figure 1) The pathologic mechanism of periodontal disease is
comprised of chronic inflammation which leads to damage and eventually irreversible
destruction of the supporting tissues of the tooth, including the underlying alveolar bone.
Periodontal disease is instigated by the accumulation of subgingival plaque in the absence
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of appropriate oral hygiene (36, 156, 250), particularly the presence of described "late
colonizers" such as P. gingivalis, P. intermedia, Tannerella forsythia and the spirochete
Treponema denticola (89, 241, 246, 253). While periodontal disease is instigated by

infection, periodontal tissue destruction is actually caused by the host inflammatory
response, principally via the constant influx of inflammatory cells and molecules such as
TNF-a,

IL-l~

and 11-17 (136, 232) (78,83, 165,255).

Periodontal disease is a progressive condition demarcated by two primary stages:
gingivitis and periodontitis. Gingivitis is the earlier and milder stage of periodontal
disease. Gingivitis is characterized by bleeding of the gums, even upon gentle brushing,
accompanied by tenderness, swelling and bright red or purple discoloration of the gums.
Subgingival plaque accumulates at the junction between the gingival margin and the
tooth. In response, inflammatory cells are mobilized to the area as the host attempts to
reduce the bacterial burden. As the infection proceeds, the gums become more inflamed,
damage accumulates and this results in gum tissue recession from the root surface of the
tooth, exposing more sensitive areas and leading to painful temperature sensitivity. The
inflammatory damage of gingivitis is generally reversible with restoration of adequate
oral hygiene. However, if left uncorrected this chronic inflammation eventually leads to
periodontitis. The hallmarks of advanced periodontal disease, periodontitis, include
destruction further into the periodontium, alveolar bone resorption as well as eventual
tooth loss (18) (225), and these pathological signs are not reversible (Figure. 1).
Part of the physiological mechanism leading to the irreversible damage of
advanced periodontal disease has to do with a physiological turnover process referred to
by Parfitt and coworkers as "coupling", in which a temporary bone resorption event
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Figure 1. Anatomy of the periodontium (as reviewed by Baker, P.J. (12, 37,
42). A) In health, gingival fibers connect the gingival soft tissue to the root of the
tooth, and the alveolar bone and cementum are connected by periodontal ligament
fibers. B) In periodontal disease, subgingival infection by Gram-negative bacteria
results in soft tissue damage, producing attachment loss and deepening the sulcus
into the periodontal pocket. Alveolar bone resorption moves the bone surface away
from the tooth root (vertical bone loss) and reduces the height of the alveolar bone
crest (horizontal bone loss). Copyright permission to reproduce figure granted by
Elsevier and (12).

followed by bone formation (86, 200). "Coupling" relies upon osteoblast precursor cells
being available and able to differentiate as well as respond to appropriate signals for bone
matrix re-formation. Normally all these components are adequately present and bone
reformation can occur, however in chronic periodontal disease bone destructive processes
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outrun the bone formation processes, effectively "uncoupling" the two and making reformation increasingly difficult to instigate (86, 200). The result is, obviously, net
alveolar bone loss.
Currently, clinical approaches to periodontal disease focus on prevention, largely
consisting of public health education and prophylactic cleaning via mechanical
debridement of the oral biofilm with tools including ultrasonic devices. Treatment for
patients demonstrating periodontal disease include scaling and root planing, which is
essentially a more extensive physical abrasion of plaque build-up than prophylactic
cleaning (7). Patients for which scaling and root planing is not an adequate therapy may
undergo various more extreme treatments including, but not limited to: pocket reduction,
in which a periodontal surgeon "peels" back the soft gingival tissue in order to remove
subgingival bacteria before replacing the tissue to reattach to the bone;

attempts to

regenerate underlying bone via graft or tissue-growth cocktails (10, 267) and, depending
upon the quality of the underlying bone, dental implants to replace lost teeth (143).
Notably, antibiotic treatment beyond a basic chlorhexidine rinse (which does not
adequately penetrate the oral biofilm) remains a complicated option due to the
inaccessibility of the target pathogens as well as the tendency of biofilm species to
development of antibiotic resistance, though studies focusing on combination therapy
have made some progress (182) (7).
As we explore treatments for periodontal disease which have been developed in
the "systemic" context, familiarity with the connections, both clinical and mechanistic,
between periodontal disease and diseases of the whole body becomes essential. For
example, systemic AMD3100 treatment has been shown to be beneficial in a mouse
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model for autoimmune collagen induced arthritis, which is used as a model for
pathogenesis of rheumatoid arthritis in humans (168). As shown below, this systemic
treatment also provides protection against periodontal disease. However, the possibility
of discovering effects which would prove deleterious to patients in whom periodontitis is
a secondary or perhaps tertiary disease cannot be under emphasized.
Periodontitis is not an isolated disease, affecting only a small portion of the
mouth. It is logical to consider transmigration of both host inflammatory and bacterial
products through the damaged epithelium lining the periodontium into the host
circulation (127). While this has important negative inflammatory connotations to the
pathological state of the entire bodily system, it also means periodontal disease can be
likewise affected by systemic approaches to treatment.

Periodontal Disease and Systemic Diseases
Periodontal disease has been shown to be bidirectionally tied to the risk and
extent of systemic diseases such as rheumatoid arthritis (18), aspiration pneumonia (100)
(258), atherosclerosis (264), heart disease (183, 273) as well as adverse pregnancy
outcomes (34).
Prevalence and severity of periodontal disease are on average two-fold greater in
patients with rheumatoid arthritis as compared to the healthy population and patients with
rheumatoid arthritis are also twice as like to suffer edentulism (18). It is worthy to note
that a common set of inflammatory players including TNF-a and IL-l suggest a bidirectional relationship between the two diseases; the inflammatory dysregulation of one
serving to worsen or, in some cases, induce the other (18, 174) (16). Porphyromonas
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gingivalis DNA has been detected via PCR in the synovial membrane from patients with

RA and may promote citrullination of various self-antigens (164) (177) (220).
Recently, evidence has compounded which suggests P. gingivalis infection is a
serious risk factor for development of RA. Like the periodontium, the synovial membrane
of patients afflicted with RA becomes heavily infiltrated with leukocytes, primarily
neutrophils, and subsequently contains numerous factors derived from those cells such as
IL-l, IL-8 and TNF-a (26) (233). Activated neutrophils within the cartilage can release
reactive oxygen species and degradative enzymes. The end result is a microenvironment
skewed towards damage of cartilage and surrounding bone (43) (87) (2) (179, 180).
Periodontitis has also been shown as a risk factor for coronary heart disease
(CHD) (128) (20, 234), the leading cause of death among humans (216). P. gingivalis has
been specifically investigated as a possible contributor to coronary heart disease due to
the chronic, inflammatory nature of periodontitis (189). Studies have shown elevated
levels of C-reactive protein (CRP), an inflammatory biomarker of cardiovascular risk
(214), in patients with periodontitis compared to patients with healthy oral cavities. The
connection between periodontitis and CRP levels could be due to induction of IL-6, a
major inducer ofCRP, by P. gingivalis (142). Increases in concentrations ofhs-CRP and,
particularly relevant to our host inflammatory data regarding AMD31 00 treatment, IL-6
have been reported in periodontitis patients and these increases are generally reversed
upon induction of periodontal treatment. Contrastingly, and perhaps also relevant to our
studies in mice, a decrease in TNF -a has been noted in the sera of periodontitis patients
which was unaffected by periodontal therapy (189).
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P. gingivalis was detected in atherosclerotic plaque deposits as early as 1999 (40)

and has continued to be regularly detected in peripheral atherosclerotic lesions, the
descending aorta, as well as aortic aneurysm specimens (262) via PCR, DNA
hybridization and conventional culture (104,141,167,248) (135).
More recently, investigators have asked whether chronic periodontitis, an
inflammatory condition with systemic ties, could furthermore contribute to deleterious
effects behind the blood brain barrier (BBB). Generally, the BBB prevents entry of
substances into the brain, however some inflammatory cytokines such as IL-6 have the
ability to cross the barrier during acute phase inflammatory response via specific
transport processes (199) (14) or more circuitous routes through fenestrated capillaries in
circumventricular organs (example: the pineal gland) which technically lie outside the
BBB (14) (203) (277). Sustained levels of inflammatory cytokines during chronic
periodontitis (ex: IL-6, TNF and CRP) have been associated with development of
cognitive decline and dementia (278) (286), (251) (58) (66). Periodontopathic bacteremia
post tooth brushing has been documented by different research groups (215) (61) as well
as the observation that P. gingival is aggregates with and survives in platelets (152). Once
the periodontopathogen enters the bloodstream, while the BBB blocks entry of the
bacteria itself, bacterial or inflammatory products resulting from the pathogens presence
may still cross. Chronic inflammation may cause heightened formation of amyloid

~

fibrils (21) and eventual contribution to neurodegeneration (203, 217) as well as
thrombus formation and damage to vascular integrity (277).
Periodontal disease has been associated with adverse pregnancy outcomes
involving preterm birth or low- weight birth, miscarriage and spontaneous abortion (34,
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62, 120), though, there are conflicting reports regarding actual benefit of periodontal
therapy during pregnancy (35).
The relationship between diabetes mellitus and periodontitis is perhaps the best
example of the bidirectional association of periodontitis and systemic diseases. While
diabetes mellitus is known to increase risk, prevalence, as well as severity and
progression of periodontitis (171, 172,256), some recent studies have provided evidence
that risk of diabetic complications is increased in patients with periodontitis as compared
with patients with healthy oral status or mild disease. Among these complications are
higher incidence of proteinuria and cardiovascular complications, including angina,
intermittent claudication, transient ischemic attack, myocardial infarction and stroke
(260) (143). These observations are important to keep in mind as we pursue potential
therapeutic strategies in the pre-clinical context. AMD3100, the bicyclam CXCR4
antagonist used in our studies, has been shown to rapidly and strongly mobilize
angiogenic cells, giving AMD3100 a potential role stimulating angiogenesis at sites of
ischemia throughout the body (48, 121).

Innate Immunity at the Periodontium

Our innate immune system contributes significantly to defense against invading
pathogens and the oral cavity is one of the most exquisite examples of this interface
between the internal body and the surrounding external environment. At the oral
epithelium-environmental interface there are several important physiological factors
contributing to a healthy immune balance, the end result being a dynamic balance of
environmental signals or stimuli eliciting just enough pro inflammatory and antimicrobial
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actions while the innate immunity also employs regulatory, anti-inflammatory
mechanisms to curb destructive inflammation (59), (136). When this homeostatic balance
is disrupted, whether via genetic defects in host immunity or by the introduction of
pathogens into the oral micro biota, periodontal disease will eventually manifest (131),
(139).
The periodontium is a diverse immune environment containing multiple cell types
to enable the host to deal with an abundant variety of environmental signals. In addition
to the keratinized, stratified squamous epithelial barrier, the periodontium is home to
tissue macrophages, neutrophils, dendritic cells within the gingival/periodontal lamina
propria, or the tissue lining the gingival crevice, Langerhans cells within the oral mucosa,
periodontal ligament fibroblasts and mesenchymal cells. All these cells types have a role
to play in mediating the oral immune response through antigen presentation, regulating
inflammation, directing pathogen clearance, as well as tissue remodeling and repair
(257).

While the induction of periodontal disease relies upon the presence of microbes,
the pathology of periodontal disease is manifested by collateral damage caused by a host
immunity attempting so arduously, yet ineffectively, to clear a pathogen that it literally
destroys everything in its path.
The innate immune cells present at the periodontal environment-host junction
wield a number of tools to aid them in orchestrating appropriate responses to various
environmental signals, among them microbial pathogens, as well as controlling internal
processes such as inflammation and self-reactivity. Among these tools are germ-line
encoded receptors which detect and discern pathogen-associated molecular patterns
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(P AMP) among the abundant and diverse microbial signals received at any given time at
the host-environmental interface. Cells such as neutrophils, macrophages, dendritic cells
and natural killer cells must orchestrate a response to invading pathogens that is both
fine-tuned enough to ignore the constantly present "commensal" microbiota, but will
rapidly act to eliminate insulting pathogens before they or the overall inflammation
causes damage to the host (124) (See Figure 2).
Toll-like receptors (TLR) are transmembrane glycoproteins made of an Nterminal leucine-rich repeat domain, a transmembrane region, and a C-terminal
cytoplasmic signaling domain (129), (136). There are currently thirteen reported toll-like
receptors and the extent of characterization regarding these receptors ranging from
thorough to putative. These receptors are typically found at junctions between the host
and environment where they can easily sense and respond to various microbial structures
(136), (236, 237) (See Figure 3).
Ideally, in response to an invading pathogen, circulating leukocytes will respond
to inflammatory signals (ex. TNF-a) released by sentinel cells such as degranulated mast
cells or local macrophages. Polymorphonuclear granulocytes (PMN) which migrate to the
infection site can respond to the invader in a variety of ways. PMNs release inflammatory
cytokines to amplify the antimicrobial reaction by recruiting various immune cells,
phagocytose microbes upon opsonization, degranulate to douse the pathogen in soluble
antimicrobial molecules such as myeloperoxidase or, as more recently discovered,
generate structures called neutrophil extracellular traps (NETs) to catch and kill microbes
(28). Currently, it is thought that NETs "catch" microbes in order to target high
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concentrations of antimicrobial components directly at them, prevent further spread of
pathogens or both (28), (268).
Critical to this process are pattern recognition receptors (PRRs) such as toll-like
receptors, NOD, and complement receptors, which are a component of the separately
functional complement system. Part of the power of these PRRs is their propensity to
form functional multi-receptor complexes in lipid rafts (19). These receptor clusters allow
for generation of large combinatorial signaling repertoires and extremely enhance the
scope of identifiable infections for mounting a context-relevant immune response (96).
(See Figure 4). TLRs which recognize extracellular microbial structures, such as
lipoteichoic acid and LPS, are located on the cell surface while TLRs which recognize
intracellular signals, such as viral or bacterial nucleic acid, are positioned on endocytic
vesicles or organelles where the odds of their interacting with their target ligands are
maximized. (See Figure 3). For extracellular TLRs, cytoplasmic signaling is initiated
upon binding of the ligand via recruitment of adaptor proteins to the TLR. The end result
is expression of specific genes to tailor the immune response and modulate inflammation
(136). In addition to physical compartmentalization, adaptor recruitment provides the
TLR response a means to activate diverse intracellular pathways to further diversify the
combinatorial immune response to microbial signals (193), (194).
While triggering of specific TLR signaling pathways by bacteria should initiate
the innate immune response as well as coordinate the induction of adaptive immunity, the
toll-like receptor interface is also a subversion opportunity for pathogens to specify
certain immune pathways to be suppressed or enhanced for their own survival benefit
(91, 136, 257).
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The complement system is a critical branch of the innate immunity, especially so
in the oral cavity where it serves in the activation and recruitment of inflammatory cells,
microbial opsonization, phagocytosis, cell lysis, as well as orchestration of the adaptive
response (90, 95, 161). The complement system cross-talks extensively with other
systems for the purpose of enhancing coordination of the host response to infection or
injury, notably, complement receptors crosstalk with Toll-like receptors (95). A mutually
beneficial cooperation has been characterized between TLRs and complement in which
complement regulates TLR activation and can regulate the activity of complement
receptors and TLRs can regulate the activity of complement receptors (91) (102, 105,
108, 290). When this exquisitely intertwined state is balanced, when the host is healthy,
TLRs and complement receptors signal cooperatively to induce a targeted response to
pathogens without producing an over-robust response. For example, complement
signaling via C3aR and C5aR in response to DAF amplifies Toll-like receptor 4-mediated
production of on IL-6, TNF-a, and IL-I while suppressing LPS-induced IL-12 production
(290).
When the state is imbalanced, as occurs when pathogens hijack signaling
pathways to interfere with elements of the immune response deleterious to its survival,
inflammation can become excessive, and tissue damage occurs.
TLR2 willingly dimerizes with TLR1 and 6 in order to expand the structural
repertoire of recognizable lipoprotein structures. TLR2 is also one example of
communication between the TLR and complement systems to potentially result
synergistic or regulatory interactions via C5aR (19), (27), (69).
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Figure 2. Chemotactic recruitment of inflammatory cells in the gingival
crevice from the review Complement and Periodontitis (90). Inflammatory
cells, the majority of which are neutrophils, are recruited to the gingival
crevice in response to chemotactic signals such as the complement
anaphylatoxin C5a (136), which can be generated either immunologically or
through microbial action (275 , 279). Although gingival crevicular neutrophils
form what looks like a "defense wall" against the tooth-associated bacteria,
they largely fail to control the infection and may cause collateral
inflammatory tissue damage (55 , 136) (191) (230) The cartoon (on the left)
represents magnification of the demarcated tooth area on the right. Reprinted
with permission.
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Dysregulated complement activation via other networks can also cause pathologic
clotting. Crosstalk between the complement and coagulation systems can directly
enhance blood clotting properties at several levels of the coagulation cascade. C3a
anaphylatoxin activates platelets to enhance their aggregation and adhesion. The other
anaphylatoxin which results from complement activation, C5a, can upregulate tissue
fibrinogen and PA inhibitor (PAl -1) expression to enhance thrombogenicity while the
complement membrane attack complex (MAC) increases potential clotting surface area.
On the other side, coagulation players can amplify activation of complement. Thrombin
cleaves C3 to C3a and C3b, and C5 to C5a and C5b. Additionally, platelets can both
initiate the classical pathway of c~mplement activation as well as elongate the lifespan of
C3b via phosphorylation of the molecule (67, 280, 281). One of the results of this closeknit relationship between the two systems is complement activated clotting which, while
it can be deleterious, when done judiciously inhibits the spread of bacteria, and so
benefits the host (162).
The immune system is also replenished via the cooperative action of complement
with other receptors, for example CXCR4, to induce mobilization of hematopoietic
stem/progenitor cells from the bone marrow (119, 149). The duties of the innate
immunity do not end, however, with the influx of PMNs, macrophages and the activation
of complement for the purpose of coating bacteria in the MAC and promoting
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Figure 3. Toll-like receptors act as multifaceted guards stationed at the border
between host and environment. A. Toll-like receptors stationed at the cell
membrane recognize microbial cell wall components such as lipoprotein, lipoteichoic
acid and bacterial fimbriae (TLR2/TLRI

or TLR2/TLR6 heterodimer) (5),

lipopolysaccharide (TLR4) or bacterial flagellin (TLR5).The ligands of some TLRs,
like TLRI0, have not been discovered. Other TLRs reside within the cell embedded
in endosomal membranes. These TLRs recognize signs of intracellular infections
such as double-stranded viral RNA (TLR3), single-stranded viral RNA (TLR7 and
TLR8) and microbial CpG DNA (TLR9).

inflammation. Relatively recently it has been discovered that the innate immunity must
also instruct the adaptive immune response in its initiation and progress (118) (65) (136).
Adaptive immune components such as T and B cell receptors as well as antibodies
possess an incredible antigenic vocabulary both in scope and specificity, however, that
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vocabulary is comprised of only random words the immune cells happen to know.
Adaptive immune specificity, the result of random gene recombination during
development, ostensibly has the ability to recognize any peptide structure. Toll-like
receptors and complement work to provide context to the adaptive response, ensuring that
its specificity and memory are applied to appropriate pathogenic signals. When this
direction goes awry, autoimmune and inflammatory disorders develop.

Microbial Induction of Periodontal Disease

The oral cavity is home to an abundant variety of microbes both bacterial and
viral. The number of bacterial species has been estimated at approximately 700, the
variety encompassing Gram positive and negative, strict aerobic and facultative
anaerobes of various morphologies (133) (202). Approximately 8 x 10 10 bacteria have
been calculated just to shed from the surfaces of the mouth in a 24 hour period, and this
quantification does not even include bacteria remaining adhered within the oral biofilm
(44).
Colonization of the oral cavity is a multistep process the individual phases of
which are demarcated by the presences of species defined as early, intermediate and late
colonizers (133). Early colonizers tend to inhabit supragingivally and dominantly
comprise the plaque there. Streptococcus species are a predominant component of the
supragingival plaque, adhering to the thin layer of saliva and gingival crevicular fluid
which coats the dentin called the pellicle (See Figure 1). Naturally, intermediate and late

17

Figure 4. The formation of TLR-based receptor clusters generates a
combinatorial repertoire to discriminate among the abundant and
diverse microbial molecules and thereby to tailor the host response.
However, pathogens may exploit the propensity of TLRs for cooperation with
heterotypic receptors by instigating the recruitment of receptors which could
deregulate effective innate immunity. The interaction between P. gingivalis,
TLR2 and CXCR4 serves as a perfect example of pathogenic subversion
targeting toll-like receptor cooperation.

colonizers use both the tooth surface and interactions with earlier colonizers to gain a
stronger foothold into the oral cavity (243) (284) (44). The later colonizers are generally
Gram negative, more anaerobic bacteria associated with disease, such as P. gingivalis,

Treponema denticola, and Tanerellaforsythia, and prefer to colonize subgingivally (243)
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(88) (157). These pathogenic colonizers induce a local inflammatory response consisting
predominantly of influx by PMNs which, if left untreated, can give rise to periodontal
disease (114) (243). Members of the "orange complex", while being generally thought of
as less pathogenic than the red complex, are also associated with forms of periodontal
disease (243) (45, 285) (See Figure 5).
P. gingivalis itself expresses an array of virulence factors to establish itself within

the biofilm, albeit as a low-abundance member, and subsequently uncouple the
inflammatory response within the gingival crevice (144). Included within this arsenal are
various structures and enzymes. P. gingivalis uses its fimbriae to interact with and
subvert Toll-like signaling on both receptor-ligand and downstream signaling levels. P.
gingivalis also possesses a set of Arg- and Lys- specific cysteine proteinases, termed

"gingipains" which it uses to target specific levels of the complement cascade, namely
the conversion of C3 and C5 for opsonization and formation of the MAC (207) (240). P.
gingivalis also uses at least one specific gingipain, HRgpA, to capture and coat its own

cell surface with C4b-binding protein, effectively masking itself from the complement
cascade (208).
P. gingivalis does not only target the complement system, as mentioned above, P.

gingivalis also possesses the ability to target the toll-like receptors. As gram-negative

bacteria, the LPS of P. gingival is should be recognized by TLR4. However, P. gingivalis
modifies its LPS to become a tetra-acylated, dephosphorylated lipid A structure (41).
This means that the LPS of P. gingivalis is biologically inert, or invisible to TLR4.
Furthermore, once periodontal inflammation is induces, correlating with increased levels
of hemin in the periodontium, P. gingivalis LPS undergoes a further modification to its
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lipid A, monophosphorylation, which converts the pathogens LPS to a TLR4 antagonist
(41,42).
The Hajishengallis

group also previously found that P. gingivalis fimbriae

interact with TLR2 and CR3 to induce an intracellular signaling crosstalk between the
receptors, the ultimate result being inhibition of IL-12p70 production via ERK1I2
signaling in macrophages and in vivo (98, 266, 276). Furthermore, the use of a CR3
antagonist reversed the ability of P. gingivalis to suppress induction of IL-12p70 which
leads to enhanced clearance of the pathogen from systemically infected mice and
protection against P .gingivalis-induced periodontitis in orally infected mIce, as
evidenced by reduced induction of periodontal bone loss (98).
P. gingivalis also induces a subversive crosstalk between the complement CSa

receptor (CSaR) and TLR2 that impairs NO-dependent intracellular killing in
macrophages (27S). P. gingivalis does this by first producing CSa (via gingipains) to bind
CSaR. CSaR then engages in crosstalk with TLR2 via ERK1I2 to inhibit that receptors
induction of IL-12p70. While this crosstalk downregulates IL-12p70, induction of
pro inflammatory and bone-resorptive cytokines (lL-IB, IL-6, and TNF-a) is actually
enhanced, further proof that P. gingivalis does not globally down or upregulate the
inflammatory response, but rather fine tunes the immune response to its own liking.
Moreover, CSaR signaling is required for P. gingiva/is to induce periodontal bone loss in
a mouse model of experimental periodontitis, showing that despite P. gingivalis ability to
hijack and subvert a variety of receptors, it is left vulnerable when these subversive
mechanisms are prevented (1S4).
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Figure 5. Development of the oral biofIlom. The oral biofilm is colonized in a

particular order. Typically, more commensal species such as S. oralis colonize
early, and thus are more closely associated with the tooth surface. Therefore
placement within the biofilm can be used as an indicator of a microbe' s
pathogenicity. For example, "orange complex" bacteria precede "red complex"
pathogens. Species in the orange complex show significant association with
increasing pocket depth as exemplified by P. intermedia and F. nucleatum. Species
in the red complex show a very strong relationship with pocket depth, adding
another parameter to determining the pathogenic qualities of microbes within the
oral biofilm: distance from tooth surface and pocket depth.

Other factors important to successful invasion of the gingival crevice by P. gingiva lis and
subsequent induction of alveolar bone loss include IFN-y and IL-6. Mice deficient in
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these cytokines suffer less periodontal bone loss due to P. gingivalis infection than their
wildtype counterparts. IFN-y is an interesting cytokine often assayed for in the
examination of the host response to P .gingivalis and AMD31 00 because of its potential
role in osteoclastogenesis. IFN-y may contribute indirectly to P. gingivalis-induced
osteoclastogenesis by stimulating monocytes and lymphocytes, although in contrast to the
IFN-y's established role inhibiting osteoclastogenesis (287) (75). IFN-y is known to also
be important to increased levels of inflammatory cytokines and leukocyte recruitment
into the periodontium, elements critical to the periodontal bone loss process (77, 86).

CXCR4 in Periodontal Disease.
It is critical that innate Immune cells successfully discriminate pathogen-

associated molecular patterns from the abundant and diverse microbial signals present at
such host-environmental interfaces as the oral cavity. Toll-like receptors(TLRs) and the
complement system are instrumental in the process of coordinating the immune response
to microbial infection via rapid activation, extensive functional cooperation and
formation of multi-receptor complexes which can include other TLRs, complement
receptors and co-receptors such as CD14 (99, 173). However, the tendency of TLRs to
cooperate with heterotypic receptors poses an opportunity for exploitation by pathogens
capable of inducing inappropriate recruitment of receptors to deregulate host immunity.
This can be especially true of pathogens which have evolved closely with the host
organism (70). P. gingivalis, a keystone pathogen in human periodontal disease, has been
shown extensively to interact in various and elegant ways with several host immune
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receptors, among them C5aR, CR3, and CXCR4, to enhance its own adaptive fitness (94,
98, 102, 103, 154).
Since TLR2 is critical in identifying the mixture of atypical LPS molecules which
decorate P. gingivalis (99) (30), it stands to reason that this receptor be strongly targeted
by the pathogen for subversion. We have previously established that P. gingivalis signals
via CXCR4 to divert antimicrobial signaling pathways initiated by TLR2 (100). TLR2
recognizes lipid A species associated with P. gingivalis LPS, however P. gingivalis also
interacts with TLR2 via its fimbriae (105). P. gingivalis induces co-association of TLR2
with other co-receptors such as CD14 and CXCR4 into lipid rafts (99) to manipulate
TLR2 signaling (See Figure 6).
It has been documented that TLR2 specifically is a target for P. gingivalis

pathogenesis. As opposed to TLR4- deficient or wild type control mice, TLR2 deficient
mice demonstrate protection against P. gingivalis-induced bone loss (30, 81). Whereas
CD 14 is summoned to facilitate activation of TLR2 by the pathogen (99), P. gingivalis
itself physically interacts with CXCR4 via its fimbriae to abrogate TLR2 activation in
human monocytes/mouse macrophages over a wide concentration range (0.2-10 Ilg/ml,
corresponding to 2 x 10 7 to 109 bacteria) (103, 291). The CXCR4 receptor is a
transmembrane G-protein-coupled receptor that, once activated by P. gingivalis fimbriae,
induces cAMP dependent protein kinase A (PKA) signaling which inhibits NF-KB
activation. At first glance this appears to be a stopgap against excessive inflammatory
upregulation, which should be beneficial to the host as chronic periodontitis is a disease
of inflammation. However, it has been shown that this interaction actually serves to
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benefit the survival of the pathogen both in vitro and in vivo (103) (See Figure 3). In
terms of the inflammatory response, this subversive signaling
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(103).
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ultimately results in inhibition of TNF-a as well as NO, the synthesis of which is also

NF-KB dependent (283) and up-regulation of IL-IO, consistent with the observation that
its transcription is positively regulated by cAMP (25). CXCR4 has also been identified as
a member of TLR4-based receptors complexes, showing that CXCR4 is bound directly
by P. gingivalis LPS (132, 263) leading to upregulation of IL-6, possibly via a cAMPresponsive element in the transcription regulation ofIL-6 (265) (56) (See Figure 7).

AMD3100: Bycyclam CXCR4 antagonist

Once the role of CXCR4 in TLR2 subversion mediated by P. gingivalis was
determined, the next logical step was to define methods by which to interrupt P.
gingivalis

influence upon the chemokine receptor. AMD3100, a bicyclam drug that inhibits SDF-l
binding to CXCR4 was found to interrupt the P. gingivalis fimbriae-CXCR4 interaction
without causing collateral signaling or receptor internalization (60, 103). Ultimately, in
mouse macrophages and human monocytes, this led to enhanced killing of the pathogen
(103).
AMD3100 was discovered accidentally as an impurity contained within one of
several commercial cyclam inhibitors while investigators were searching for potential
anti-HIV compounds (50). Upon characterization, the bicyclam impurity was synthesized
itself, modified and subsequent studies determined this bicyclam class of molecular target
as CXCR4 (48) (51) (54) (228). The compound designation, JM3100, was changed to
AMD3100 in order to indicate the developer. AMD3100 was subsequently found to
inhibit T-tropic HIV strains via selectively inhibiting the interaction between HIV gp120
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to CXCR4 after it has bound to the CD4 receptor, but prior to initiation of cell membrane
fusion by HIV gp41 (68) (48). The antiviral activity of AMD3100 was further
characterized in a study which demonstrated the compound reduced viral load in SCIDhu Thy/Liv mice infected with a CXCR4- using clinical HIV isolate (47). AMD3100 can
only suppress CXCR4 using viruses, such as the X4 and R5 tropic HIV variants, as
opposed to variants which use CCR5 to facilitate entry (72). AMD31 00 is now known to
be both a CXCR4 antagonist as well as a CXCR7 agonist, though the effects of the later
interaction are still being discovered (123) (190) (64). AMD3100 allosterically inhibits
SDF-l binding to CXCR4 and thus the subsequent Ca2+ influx resultant of SDF-lCXCR4 interaction (125) (48, 71, 106). Specifically, AMD3100 binds to three acidic
residues in the main SDF -1 binding pocket of CXCR4 (Asp 171 in transmembrane
domain [TM]-IV, Asp262 in TM-VI and Glu288 in TM-VII) (74) (106) (219) (282).
It has also been discovered that AMD3100 is a rapid and efficient stem-cell

mobiliser (33), and this discovery has implications for stem cell transplantation and
treatments for cancers such as multiple myeloma and non-Hodgkins lymphoma (57).
Bone marrow stromal cells constitutively display SDF-l which keeps CXCR4 expressing
CD34+ stem cells anchored into the marrow. AMD3100 interferes with this anchoring,
loosing the cells from SDF-l (32) (71) and allowing them to mobilise into the peripheral
circulation

(272)

(32).

Under

healthy

conditions,

very

few

haematopoietic

stem/progenitor cells can be found circulating in the peripheral blood, peripheral levels
typically increasing only in response to such emergency situations as infection or trauma
(149) (166) (147). Under the name Plerixafor, the CXCR4 antagonist has been approved
as a subcutaneous treatment, in combination with G-CSF, in the U.S. to mobilize
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haematopoietic stem cells for collection and treatment

III

adults with non-Hodgkins

lymphoma or multiple myeloma (12S).
Upon a single subcutaneous dose of 0.4-0.24 mg/kg (116, ISS) AMD3100,
healthy volunteers demonstrated a dose dependent, transient increase in circulating
CD34+ cells as well as other leukocytes, with mobilization into the periphery peaking
about nine hours post administration in the highest concentration. The pharmacokinetics
for subcutaneously administered AMD3100 are mostly linear over tested dose ranges
(S7). It is necessary to note that certain elements of the innate immunity which are also
targets of P. gingivalis-mediated subversion regulate HSPC mobilization. Examples of
these include the complement cascade, neutrophils and Toll-like receptors (181) (149,
210, 212, 213) (186). CS, specifically the CSa cleavage fragments spared by P. gingivalis
gingipain degradation, was shown to be a critical component to HSPC mobilization via
G-CSF and or zyomasan (149) (148) by showing that CS deficient mice are uniformly
poor mobilizers. It is important to note that, in relation to HSPC mobilization, there
seems to be a passing back and forth of activation between granulocytes, particularly
neutrophils, and the complement cascade, with granulocytes being activated the BM by
complement cleavage fragments, aiding in HSPC retention signal perturbation, and
further CS activation. Once the granulocytes have paved the way for HSPC escape into
the peripheral circulation, they are stimulated again by C5a to release cationic peptides
like cathelicidin and

~2-defensin

as well as other metalloproteinases (148, 149).

Like the other methods of mobilization, AMD3100-directed HSPC mobilization
likewise relies upon complement activation for success, however at different levels of the
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complement cascade. AMD3100 directly activates the complement cascade at the C5
level by inducing granulocytes to release proteases (149).
As mentioned above, AMD3100 has been shown to aid in controlling
inflammation in a mouse model of collagen-induced arthritis (168). AMD31 00 treatment
reduced the severity of autoimmune collagen-induced arthritis (CIA) in IFN-yR-deficient
DBAIl mice. The delayed-type hypersensitivity response to the auto antigen, in this
model collage type II, was reduced upon systemic AMD3100 treatment. The authors of
the study concluded that AMD3100 must act upon chemokine-mediated attraction of
leukocytes into joint tissues, a pathogenic process comparable to the chemoattraction of
leukocytes into the periodontium during periodontal disease. The authors hypothesized
involvement ofSDF-l and injected SDF-l into periarthritic tissue and noted a subsequent
inflammatory response. This reaction was inhibited by AMD3100. In these studies,
treatment was initiated between the time of immunization, or, the experimental induction
of the inflammatory disease, and the appearance of symptoms. While not exactly a model
for "therapeutic" treatment, these studies indicated that CXCR4 antagonism post
induction of disease could provide a clinical benefit.
CXCR4 expression can be observed in the sites of several flavors of pathology,
and, depending upon the mechanistic role of CXCR4 in pathogenesis, CXCR4 blockade
could be an effective "theme" for therapy across many diseases of separate etiologies.
CXCR4 has been associated with a variety of infectious diseases. Not only is CXCR4 a
critical point of entry for HIV tropic virus cells (17) and as shown here a critical target of
signal transduction in P. gingiva/is mediated periodontitis. CXCR4 blockade has been
reported to reduce viral load within the CNS of West Nile Virus infected mice and
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significantly improved infection (170). Due to the broad connections of CXCR4 to
disease

processes,

molecules

targeting

the

co-receptors

have

understandably

demonstrated side effects involving heart function and thrombocytopenia ostensibly due
to inhibition of other essential functions of CXCR4 (109).
CXCR4 expression has been noted in some breast cancer cell lines (185) and
CXCR4 has also been connected to progression of diverse malignancies of the brain,
including

intracranial

glioblastoma

and

medulloblastoma

(222).

Waldenstrom

macroglobinemia (WM) is a lymphoma of B cells and the trans-endothelial migration of
these cells relies upon CXCR4 signaling, ostensibly through SDF-l (192) and CXCR4
blockade may be a beneficial adjunct to existing therapy. In a mouse model of anaplastic
thyroid carcinoma, AMD3100 was shown to reduce tumour growth (52). CXCR4
activation may enhance pituitary adenoma development, as CXCR4 and SDF-l are both
overexpressed in human pituitary adenomas (15). AMD3100 treatment decreases human
colorectal cell migration in Boyden chamber experiments as well as in vitro assays
designed to measure invasion across an 8-/.lm pore size polycarbonate membrane precoated with a layer of basement membrane matrix (151). Very recently, one group
published a study indicating the SDF-I-CXCR4 signaling axis in pancreatic cell invasion,
at least in vitro, showing that SDF-l activation of CXCR4-positive pancreatic cells
induces invasion, demonstrating yet another pathogenic process to which abnormal
chemotaxis signals, specifically through CXCR4, may playa critical role (153).

Considering CXCR7 and AMD3100.
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It was originally thought that AMD31 00 was a specific allosteric antagonist of the

monogamous CXCR4-SDF-l binding pair (106), however, in 2005 CXCR7 was
described as a second receptor for the SDF -1 molecule which, in humans, finds
expression in embryonic neuronal and heart tissue, hematopoietic cells and activated
endothelium (31, 117) (13). CXCR7 is a heptahelical G-protein coupled receptor (13)
(73) which recognizes CXCL12 but upon activation does not induce typical GPCR
mobilization of Ca++ (288), G-protein-mediated signal transduction and cell migration
(31). Instead, activation of the B-arrestin pathway and subsequent scavenging of the
ligand has been shown (190, 259). CXCR7 can also heterodimerize with CXCR4 to
abrogate the G protein complex signaling (150).
Like CXCR4, pathogenic roles, especially in malignancy and metastasis, are
being elucidated for CXCR7, an example being the ability of CXCR7 to signal through
PLC/MAPK pathway increasing cell survival within gliomas (64, 107). In metastatic cell
lines CXCR7 overexpression correlated with enhanced proliferation and in clinical
correlative studies upregulated CXCR7 expression was connected to increased
aggressiveness of prostate cancer (274) as well as in vivo growth of breast and lung
tumours (176). Also like CXCR4, CXCR7 expression is necessary for successful
development, as CXCR7 deficient mice die perinatally due to heart valve malformations
(238). While different theories as to the specific mechanism have been proposed, the
cause for this perinatal fatality has been linked to the role of CXCR7 in embryogenesis.
Specifically, the chemokine receptor has a role in directing the migration of primordial
germ cells (269) (23).
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The discovery that CXCR7 binds SDF-l logically led to the hypothesis that
AMD3100 must also interact with the chemokine receptor. Ligand recognition by GPCRs
is followed by a conformational change in the receptor to activate the associated
heterotrimeric G-protein. When a receptor, such as CXCR4, is bound by a molecule other
than its intended ligand, at a separate site on the receptor, allosteric modulation can occur
(123). This is the case with AMD3100 and CXCR4, because AMD3100 allosterically
inhibits SDF-IICXCR4 interaction. In the case of CXCR7, however, binding of
AMD3100 to the receptor actually increases the receptors affinity for SDF -1, making
AMD3100 a positive allosteric ligand for this receptor, including at in vitro study
concentrations (123, 169) (190). AMD3100 administered alone selectively recruits

~

arrestin to CXCR7 in mammalian cells instead of CXCR4. These recent developments
make CXCR7 a worthwhile receptor to study in periodontal disease, especially as studies
involving the action of AMD3100 proceed.

Treatment of Periodontal Disease

P. gingiva/is is a low-abundance anaerobic bacterium which plays a critical role

in the pathogenesis of periodontal disease, a polymicrobial as well as inflammatory
condition. P. gingivalis manipulates its environment, the deep gingival crevice, in a
variety of ways to enhance its own survival, not least among them triggering quantitative
as well as qualitative changes in the composition of the oral micro biota which in tum
promotes dysbiosis and consequent periodontal inflammation (97). At this time, it seems
as though periodontal bone loss requires a triumvirate of players, including the host
complement, P. gingivalis itself and the commensal microbiota, because germ-free mice

31

or conventionally raised C3a and C5aR-deficient mice did not develop bone loss post P.
gingivalis inoculation (97, 154). While P. gingivalis is thus identified as a "keystone"

pathogen and does employ various tactics to out-maneuver the host response, as well as
all but the most invasive clinical interventions, targeting this low-abundance pathogen
may reverse its community-wide impact and thus prove important to treatment to
periodontal treatment and prevention.
This study focused on the crosstalk events induced by P. gingivalis fimbriae
between TLR2 and an associated co-receptor chemokine receptor 4 (CXCR4). P.
gingivalis exploits CXCR4 to undermine host signaling and promote its own adaptive

fitness. In this way P. gingivalis acts like a conductor which has hijacked the orchestra of
host immune receptors, directing them not to maintain a homeostatic balance, but rather
to drive a chronic inflammatory state. This selectively nonproductive response benefits P.
gingivalis while causing extensive collateral damage in the periodontal tissues as well as

potentially increasing the risk and extent of systemic diseases such as rheumatoid arthritis
(18), aspiration pneumonia (100), atherosclerosis (264) and heart disease (183, 273).
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Figure 7. P. gingiva/is antagonizes TLR4 but not TLR2 at the receptor level. P.
gingivalis targets TLR2 at the downstream signaling level via CXCR4 exploitation.

P. gingiva/is uses an elaborate system of lipid A phosphatase and deacylase
activities that modify the lipid A structure of its lipopolysaccharide (41). These
modifications result in lipopolysaccharide molecules that can either evade or
actively antagonize TLR4 activation (depicted as a homodimer; TLR4/4) (41).
Although the activation of the TLR2/TLRI

heterodimer (TLR2I1) is not

antagonized at the TLR receptor level, P. gingivalis instigates a molecular crosstalk between the CXC-chemokine receptor 4 and TLR2/ l. Unlike CD14 which
facilitates TLR211 activation by the pathogen (55 , 99), CXCR4 suppresses TLR2
signaling (103). Mechanistically, P. gingiva/is uses its fimbriae to bind CXCR4 and
induce cAMP-dependent PKA signaling, which in turn inhibits the activation of
nuclear factor-lcB rNF-lcB) activation(103). Reorinted with oermission.
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CHAPTER TWO: MATERIALS AND METHODS

Bacterial strains and culture conditions. P.gingivalis ATCC 33277 was grown
anaerobically from frozen stocks on modified Gifu anaerobic medium-based blood agar
plates (Nissui Seiyaku Co., Tokyo, Japan) for 5-6 days at 37°C under microaerophilic
conditions. P. gingivalis was also grown in reduced Trypticase Soy Broth (TSB; BD)
supplemented with yeast extract (1 gram per liter; BD), menadione (1
Aldrich), and hemin (5

~g

~g

per ml; Sigma-

per ml; Sigma-Aldrich). The medium was reduced for 24

hours under anaerobic conditions by equilibration in an atmosphere consisting of 10%
CO 2 , 10% H2 , and 80% N 2 .

Animals. Female BALB/c mIce were obtained from The Jackson Laboratory.
C57BLl6 conditional CXCR4-deficient mice (with their respective wildtype control
mice) were provided by Dr. Gregg Rokosh (University of Louisville) and were housed in
conventional vivarium conditions. Inducible conditional knockout mice were generated
using acre recombinase modified with an estrogen receptor ligand-binding domain. This
modified cre recombinase was non-functional until induction with tamoxifen at four
weeks of age (6).
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Subcutaneous osmotic pump implantation in mice. ALZET osmotic pumps
were loaded prior to insertion following manufacturer instructions. Mice were weighed
prior to implantation to assure adherence to the pump implantation weight guidelines.
Anaesthesia was induced over 2 minutes by isoflurane (Butler Schein Animal Health)
inhalation through a vaporizer (3% isoflurane and 100% O2 ). Surgical anaesthesia was
confirmed by pinching the foot pad and observing reaction. Artificial tears (Butler Schein
Animal Health) were applied to avoid eye injury during surgical implantation! discomfort
upon waking. The target area for subcutaneous implantation was sanitized using 70%
ethanol and then Nolvasan 4% antibicrobial solution (Butler Schein). The area was
shaved using surgical preparatory blades and the area was sanitized again with Nolvasan
rinse. A subcutaneous incision was made dorsolaterally, posterior to the scapulae. The
incision was made anteriorly so that the pump, once inserted, would slide posteriorly.
This was done so the mouse could not access and chew the sutures or staples before the
wound was adequately healed. Alzet osmotic minipumps (model #2004; Alza, Palo Alto,
CA) were subcutaneously implanted "delivery portal first" within a pocket large enough
to allow a relatively free movement of the pump without allowing the pump to tum or
slip down the flank of the animal. The incisions were closed with a wound closing stapler
system (BD). Mice were monitored and on Day 10 staples were removed.

In vivo mouse periodontitis model. The P. gingivalis-induced periodontal bone
loss model used was essentially as originally developed by Baker and colleagues (12) as
follows. 10-12 week old wild-type or CXCR4 conditional deficient mice were fed water
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with antibiotics (SOOllg sulfamethoxazole/ml and 400 Ilg trimethoprim Iml) ad libitum for
ten days to suppress the normal flora and create a more favourable niche for P. gingivalis
colonization as the mouse is not a natural host to P. gingivalis. This was followed by 3
days of regular water ad libitum to allow the antibiotics to clear the system. P. gingivalis
33277 was grown on TSB or GAM blood agar plates for 3-6 days in anaerobic buckets
and suspended into 5 ml PBS. An OD 600 reading was taken to measure CFU and the
bacteria were spun down at 4000 RPM for 10 minutes. Bacteria were resuspended at 2 x
lOlO/ml. The bacteria were added to 2% CMC (the oral gavage vehicle) at a 1:1 ratio so
that the final concentration of bacteria should be 1 x 1010/ml.
Mice were orally infected five times at 2-day intervals with 109 CFU P. gingivalis
suspended in 100111 2% carboxymethylcelluloselPBS. Sham-infected control animals
received 2% carboxymethylcellulose in PBS alone. Mice were fed using a 1 ml syringe
and a 22 xl" W11-114 animal feeding needle. A separate needle for the P. gingivalis and
sham infected mice was used and the needles were kept separate at all at times including
when they were cleaned. Needles were treated with a D/Rnase solution to eliminate P.
gingivalis DNA cross contamination. See Figure S.

Analysis of alveolar bone resportion. Six weeks after the final infection, mice

were euthanized via C02 inhalation. After euthanization, the mice were decapitated. The
mouse heads were boiled for 15 minutes under 15 Iblin2 of pressure and subsequently
defleshed. The skulls were then immersed in 3% hydrogen peroxide overnight at room
temperature to remove any remaining musculature and washed with deioinized water. To
ensure that any residual bacteria and/or tissues were removed from the teeth, skulls were
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sonicated at 4 volts in 1% bleach for 30 seconds, rinsed with water, and then gently
brushed with toothpaste for 30 seconds. They were rinsed clean, swirled in distilled water
for 30 seconds, and then once again sonicated at 4 volts in 1% bleach and rinsed clean

A.

10 Days
Antibiotics,
4 days water
ad libitum

Day 4 water ad
libitum, insert
pumps
su bcuta neOl

9

5 infections 10
every other day

Day 60 mice are
sacrificed and tissues
are collected

Figure 8. Baker model of oral infection. A. Mice
B.

are given broad spectrum antibiotics to clear
Mouse upper j aw

normal flora and create a niche for P. gingivalis.
After a rest period to clear antibiotics from the
mouse system, mice are infected every other day.
eft mohl r"i

On day 60 mice are euthanized. B. Schematic of
gingivae dissection following euthanasia of mice.

with deionized water. The cleaned teeth were stained for 5 minutes with 0.5% Eosin Y
TS, 30 seconds with 1% Methylene Blue (Ricca Chemical Company, Arlington, TX) and
rinsed with deionized water to remove excess dye. Skulls were allowed to air-dry prior to
measurement of the alveolar bone.
Assessment of periodontal bone loss in defleshed maxillae was performed under a
dissecting microscope (x40) fitted with a video image marker measurement system
(model VIA-170K; Fryer, Huntley, IL) standardized for measurements in millimeters
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(mm). Specifically, the distance from the cementoenamel junction (CEl) to the alveolar
bone crest (ABC) was measured on 14 predetermined points on the buccal surfaces of the
maxillary molars (12). The 14-site total CEl-ABC distance for each mouse was
subtracted from the mean CEl-ABC distance from the group of sham-infected mice;
results were expressed as millimeter change in bone, and negative values indicated bone
loss compared with sham-infected controls (12). All animal procedures received
Institutional Animal Care and Use Committee approval and were in accordance with
federal guidelines for the care and use of laboratory animals.

RNA Isolation, eDNA synthesis and RT -peR of host genes. Palatal and buccal
gingival tissue immediately adjacent to maxillary molars was dissected and stored at 70°C in RNALA TER. RNA was extracted using the Qiagen RNeasy Mini Kit and
quantified at 260 and 280 nm using a NanoDrop spectrophotometer. The RNA was
reverse transcribed using the qScript™ cDNA SuperMix (Quanta Biosciences) and
quantitative real-time PCR was performed using the ABI 7500 Fast System, according to
the manufacturer's protocol (Applied Biosystems) in 20 Ill. All TaqMan probes, sense
primers and antisense primers for expression of genes were purchased from Applied
Biosystems (154). The amplification conditions for all qPCR reactions were as follows:
20 seconds at 95°C, then 40 cycles of two steps, 3 seconds at 95°C to denature, and 30
seconds at 60°C for annealing and elongation. All changes in gene expression were
expressed as the difference in threshold value between GAPDH and the gene of interest
in experimental groups versus the negative control group. See Table 2.
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DNA isolation. 24 hours after the last infection mice were euthanized, maxillary
palatal, and buccal gingival tissues as well as the tooth and immediate bone were
harvested (sham mice first to avoid contamination), placed in the lysis buffer (ATL)
provided with the Qiagen Dneasy kit and lysed overnight at 56°C with occasional
agitation. DNA was then harvested using the Qiagen DNeasy and stored at 4°C short
term or -20°C long term. The concentration and purity of each DNA sample were
measured via spectrophotometry at 260nm (ND-IOOO Spectrophotometer, NanoDrop
Technologies, Inc, Wilmington, DE). Using the concentration estimate gained from the
spectrophotometric readings the DNA preparations were diluted to give roughly
equivalent amounts of DNA per PCR reaction. Quantitative real-time PCR for total
bacteria was done using Taqman primers to 16S (137) and for P. gingivalis using
Taqman primers designed for ISPG 1 in a final reaction volume of 20111 (Applied
Biosystems). See Table 2. Total bacteria and P. gingivalis genomic copy number were
quantified using a standard serial dilution of DNA extracted from P. gingivalis broth
culture. The broth culture was quantified by CFU in order to construct a standard curve.

Titanium Coil Chamber Implantation. Isofluorane anesthetized Balb/c mice were
dorsolaterally implanted with a surgical-grade titanium coil chamber. Following a 7 day
healing period, P. gingivalis (10· CFU in 100 III of PBS) was injected into the chambers of
each mouse. Various doses of AMD3100 were co-injected in the same 100j.l1 volume.
Chamber exudates were harvested from mice at indicated time points and centrifuged at 1000
rpm for 5 minutes. Subsequently, recruited cells were phenotypically characterized by flow
cytometry, supernatants were used to determine viable counts of P. gingivalis, and cytokines
were analyzed using EIA (EB Biosciences) or Luminex-IOO/multiplex cytokine analysis
system (Upstate). See Figure 9.
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Fig. 9. Implantation of titanium steel coil for subcutaneous chamber model.

Mice were typically anesthetized using Isofiurane/Oxygen mix and measures for
pain alleviation were followed as per the veterinarian recommendations, allowing
for non-interference with host response analysis.

Statistical analysis. Data were evaluated by analysis of variance and the Tukey-

Kramer multiple comparisons test using the InStat program (GRAPHP AD Software, San
Diego, CA, USA). Where appropriate (comparison of two groups only), Student's twotailed unpaired t-tests were performed. The level of significance was taken as p < 0.05.
All experiments were performed at least twice for verification.
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Table 1. Bacterial Strains used in this Study.
Bacterial Strain

+::.

P. gingivalis A TCC

33277

Description

Source

Gram-negative, rod-shaped, anaerobic
pathogenic bacterium.

ATCC

Anaerobic rod; oral bacteria, orange complex

ATCC

F. nucleatum A TCC

25586

Table 2. Primers used in this study.
Primers

Primer Sequence (5' -

3')

(163)

Bacterial Squences

+:>.
N

Source

5' Universal 16s

5'TCCTACGGGA GGCAGCAGT-3'

(163)

3' Universal 16s

5'-GGACTACCAGGGTATCTAATCCTGTT-3'

(163)

Universal 16s Reporter

5'-FAM-CGTATTACCGCGGCTGCTGGCAC-TAMRA-3'

5' P. gingivalis ISPG 1

5' -CGCAGACGACAGAGAAGACA-3'

3' P. gingivalisISPG 1
P. gingivalis ISPG 1 Reporter

This Study

5'-ACGGACAACCTGTTTTTGATAATCCT-3'

This Study

5' -FAM-TCCGCCTCGCTCCGAT-TAMRA-3'

This Study

CHAPTER THREE: SYSTEMIC AMD3100 ADMINISTRATION PREVENTS
ALVEOLAR BONE RESORPTION IN P. GINGIVALIS INFECTED MICE

Introduction

The inflammatory immune response is critical to protection against oral pathogens
but is ultimately also the driving factor in chronic periodontitis. Some investigators have
attributed this pathogenesis at least partly to a spatial shift in the constant inflammatory
infiltrate closer to the bone surface (86). Graves and coworkers reported in a non-human
primate model of experimental periodontitis that the inflammatory front shifts closer to
the crest of the alveolar bone in association with increased osteoclast formation. This
process was significantly alleviated by blockade of IL-1 and TNF -u (84, 86). Other
investigators have noted that the closer the inflammation comes to the bone, the more
aggravated the bone loss becomes (229) (221) (198). These observations were taken to
mean that, by inhibiting inflammatory migration from the sub-epithelial connect tissue
closer to the one, that progression from gingivitis to periodontitis could be prevented.
Toll-like receptors (TLRs) detect and respond to microbial infection via rapid
activation of inflammatory and antimicrobial responses in cooperation with other innate
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immune receptors with which they form multi-receptor complexes in membrane lipid
rafts of front-line defense cells (e.g., neutrophils and macrophages) (263).
However, the tendency of TLRs to functionally associate with heterotypic
receptors poses an opportunity for exploitation by microbial pathogens capable of
inducing inappropriate lipid raft recruitment of receptors that could subvert host
immunity (96).
We have previously shown that Porphyromonas gingivalis, a keystone pathogen
in periodontal disease (97), interacts with several innate immune receptors, including
complement receptors and the CXC chemokine receptor 4 (CXCR4), in ways that
enhance its own adaptive fitness (101) (103) (154) (275, 276). With regard to CXCR4,
we have shown that P. gingivalis uses its surface fimbriae to directly bind and activate
CXCR4 to subvert antimicrobial signaling initiated by TLR2 (103) (205).
Specifically, P. gingivalis induces co-association between CXCR4 and TLR2 in
lipid rafts, leading to a subversive crosstalk pathway in which cAMP-dependent protein
kinase A signaling inhibits intracellular nitric oxide production. This activity, in tum,
impairs the killing function of leukocytes (103) suggesting that P. gingivalis exploits
CXCR4 to evade host immunity and, perhaps, to persist in the periodontal tissue and
cause disease (231).
However, in our previous studies we did not examine whether the exploitation of
CXCR4 by P. gingivalis enhances its ability to cause periodontitis. To address this
hypothesis, we now determined whether a specific and potent antagonist of CXCR4, the
bicyc1am drug AMD3100 (60), can inhibit P. gingivalis-induced periodontitis in the
mouse model. Our current results show that AMD31 00 impairs the ability of P. gingivalis
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to cause bone loss by interfering with its colonization in the murine periodontal tissue.
These findings provide proof of concept that CXCR4 antagonists may be promising
therapeutics for the treatment of human periodontitis.
Prior to these studies, AMD3100 was used m combination with preexisting
therapeutic molecules (G-CSF and GM-CSF) in a clinical setting to increase circulating
peripheral blood stem cells and it has been proposed that CXCR4 blockade may have a
role to play in treating leukemia due to shared surface expression of adhesion molecules
and CXCR4 on leukemic precursor cells and HSPCs (231) (24) (218, 247)
Generally no single animal model completely recapitulates the pathophysiology
of human disease. However, animal models possess utility in testing specific mechanistic
hypotheses involving the pathology periodontal disease (85). In the Baker model of
periodontitis, induction of several inflammatory cytokines can be reliably observed in
conjunction with alveolar bone loss. Therefore, modulation of cytokine expression in the
gingival tissues is analyzed along with the more clinical parameter of bone loss.
It is critical to demonstrate cause-and-effect relationships when studying potential

therapeutic compounds and these studies cannot be addressed in humans (85) as clinical
trials can be initiated only after safety and efficacy have been demonstrated in animal
models. In this study we show that treatment both prior to and post P. gingivalis mediated
induction of disease arrests the progress of inflammatory bone loss.

Results
AMD3100 prevents development of periodontal bone loss in mice infected with P.
gingivalis
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CXCR4 antagonism leads to enhanced clearance of P. gingivalis in mouse
macrophages/human monocytes (103), therefore we hypothesized that treatment with
AMD3100 would protect mice from periodontal bone loss in the Baker model of chronic
periodontitis. Physiological protection could be due to either: I) enhanced clearance of
the bacteria, or 2) inhibition of P. gingivalis-mediated inflammatory tissue destruction by
the immune system. To account for both possibilities, systemic treatment with AMD31 00
was initiated 24 hours prior to initial P. gingivalis inoculation. In order to ensure the
antagonist was delivered for an adequate amount of time to produce a measurably
protective effect, Alzet mini-osmotic pumps administering 0.25 )ll/hr at a steady rate for
four weeks were subcutaneously implanted dorsolaterally in BALB/c mice. 600 )lg
AMD3100 was delivered a day, corresponding to a steady serum level of about I )lg/ml
(168). This concentration has previously been found to effectively block CXCR4 in cell
culture experiments (103, 205). Systemic treatment is advantageous because of
AMD31 00' s low oral bioavailability (110, 271) as well as the extensively documented
successful administration of AMD3100 (in terms of its efficacy in CXCR4-mediated
diseases), ranging from I to 5 mg/kg mouse body-weight (113, 121, 224, 242).
Systemically administered AMD3100 has been shown to be safe both in mice and in
human phase I clinical trials (110). Moreover, our laboratory has shown that a single
intraperitoneal injection of AMD31 00 results in enhanced clearance of P. gingivalis from
the peritoneal cavity.
Continual

systemic

administration

of AMD3100

completely

abrogated

periodontal bone loss caused by P. gingivalis in Balb/c mice (p < 0.01; See Figure 10), in
stark contrast to mice receiving only PBS which developed significant bone loss relative
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to sham-infected controls. AMD3100 treatment in the absence of bacterial infection did
not affect bone loss in the mice.
Since P. gingivalis interacts with several immune receptors involved in
inflammation (TLR2, TLR4, CXCR4) and since one of the downstream targets of these
interactions was NF-KB, we elected to survey two mice from each experimental group
using a 96 well gene array designed to identify trends in the NF-KB-mediated
inflammatory profile. While differences in gene expression assayed in this experiment
were not significant, there was an observable trend in differences between infected
treated and untreated mice. Later, we used this information to do RT-PCR in CXCR4 KO
mice, experiments in which starting amounts of gingival tissue were limited, and assay a
targeted group of inflammatory/osteoclastogenic genes. In the CXCR4 KO experiments,
the trends we observed using the arrays in AMD3100 treatment experiments were
confirmed. One of the most striking correlations was the observation of high amounts of
mRNA for several inflammatory genes without the presence of bone loss in sham
infected, CXCR4 KO mice, just as in the AMD3100 treated, sham infected mice (See
Chapter Four).
We noted a difference in relative expreSSIOn of pro inflammatory mediators
important to the progression of periodontal disease. By day 60, AMD31 00 treatment had
caused down-regulation ofIL-6 and upregulation of TGF-~ in P. gingivalis-infected mice
relative to untreated mice. We noted upregulation of RANK -L in one AMD31 00 treated
mouse, but osteoprotegerin was also upregulated in the same mouse so it's reasonable to
attribute the lack of bone loss to the decoy receptor competing with RANK-L resulting in
inhibition of osteoclastogenesis. Long term AMD3100 treatment alone caused
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downregulation of IL-6, and RANK-L and upregulation in

IL-l~,

TNF-a,

TGF-~

and

OPG relative to no treatment. These mice did not display alveolar bone loss, despite an
apparent upregulation of inflammatory cytokine production.
These data indicated that AMD31 00 treatment protects mice from P. gingivalismediated bone loss when the drug is administered prior to exposure to the pathogen and
for an extended duration. This protection appeared to be due at least in part to a shift in
the inflammatory response to P. gingivalis as a result of CXCR4 blockade.

We

concluded, upon surveying the inflammatory response at day 60, that the downregulation
of IL-6 in P. gingivalis-infected AMD3100 must be due to a combination of CXCR4
blockade and resolution of P. gingivalis-mediated inflammation prior to day 60.
However, the elevated

IL-l~

and RANK-L levels in infected, treated mice conflict with

the later conclusion, so we decided to ask whether the infection was actually being
resolved early during the oral chronic periodontitis model.
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Figure 10. Preventive treatment with AMD3100 abrogates P. gingiva/is-induced
periodontal bone loss. BALB/c mice (10-12 weeks of age) were administered
AMD31 00 (or PBS control) through osmotic minipumps which were implanted
subcutaneously 24 hours prior to oral infection with P. gingivalis (or vehicle only;
sham) as described in the Methods. The mice were euthanized six weeks after the
last inoculation with P. gingivalis, gingivae were dissected for RT-PCR and bone
loss measurements were performed in detleshed maxillae. Data are means ± SD (n =
5 mice per group); negative values indicate bone loss in P. gingivalis-infected mice
relative to sham-infected controls. **p < 0.01 compared to control and all other
experimental groups. AMD, AMD3100; Pg, P. gingiva/is.
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Systemic AMD3100 treatment effectively eliminates P. gingivalis from the oral
cavity early in the oral infection model.
We next investigated whether AMD3100 treatment actually enables the host to
clear the pathogen from the oral cavity, or if P. gingivaZis persists in the oral cavity
during AMD3100 treatment but is not able to incite pathologic bone loss. This is
important because, if the P. gingivalis manages to persist despite the AMD3100
treatment, once treatment is removed P. gingivalis would be free to instigate disease.
CXCR4 blockade inhibits survival of P. gingivalis in mouse macrophages, therefore we
hypothesized that the protective effect of AMD31 00 treatment in the context of chronic
periodontitis is due to enhanced clearance of the bacteria.
To this purpose, an abbreviated version of the Baker oral model of disease was
used. Mice were given ten days of broad spectrum antibiotics and three days regular
water ad libitum as in the regular model. 24 hours prior to the initial P. gingivalis
inoculation, 14 day osmotic pumps were implanted subcutaneously in mice. Seven days
after the final (fifth) infection, mice were euthanized and periodontal tissues were
collected. qRT-PCR targeting ISPG 1, a high-copy number gene, was used to detect P.
gingivalis in the soft and hard tissues of the periodontium. There was a statistically
significant increase in copy number of P. gingivalis in untreated mice (p< 0.01, See
Figure 11).
However, ISPG 1 copy number in P. gingivalis-infected, AMD3100 treated mice
was indistinguishable from sham infected mice. There was also a statistically significant
trend in the total bacterial load (both aerobic and anaerobic) as measured by
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Figure 11. Effect of AMD3100 on the numbers of P. gingiva lis or total bacteria
in the murine periodontal tissue. BALB/c mice (10-12 weeks of age) were
treated with AMD31 00 (or PBS control) and infected with P. gingivalis (or vehicle
only; sham) as described in the legend to Figure 1. The mice were sacrificed 7
days after the last inoculation with P. gingivalis. The numbers of P. gingiva lis and
of total periodontal bacteria in the periodontal tissue were determined using
quantitative real-time PCR of the ISPgi gene (P. gingiva lis) or the 16S rRNA gene
(total bacteria). Host gene expression was determined via qRT-PCR. Data are
means ± SD (n

=

5 mice per group). *P < 0.05;

groups. AMD, AMD31 00; Pg, P.

~in~ivalis.
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** P < 0.01

between the indicated

16S copy number. There was a significant increase in total bacterial load in untreated
mice infected with P. gingivalis, while the total bacterial load remained at sham infected
levels in mice also treated with AMD3100, (p< 0.01, See Figure 11). We previously
showed that P. gingivalis colonizes the oral cavity in specific-pathogen free mice at low
levels and causes an elevation of the total cultivatable commensal bacterial load, and this
shift in the commensal bacteria is essential to induction of bone loss (97). The finding
that P. gingivalis causes a pathologic, quantitative increase in commensal bacteria and
that AMD3100 treatment reverses that shift supports our previous conclusion that P.

gingivalis plays the role of a keystone pathogen within the oral biofilm. Taken together,
these data indicate that systemic AMD3100 treatment leads to elimination of P.

gingivalis from the oral cavity and prevents the quantitative increase in the oral
commensal microbiota attributable to the successful colonization of P. gingivalis (97).
Again, we used 96 well assays to look for changes in inflammatory genes
downstream ofNF-KB. While we only used two mice per group, as above, we noted IL17 expression was nearly undetectable in PBS Sham (negative control) mice versus
infected mice and lower RANK-L expression in AMD3100-treated, infected mice versus
the other groups. Relatively lower gingival expression of inflammatory mediators,
including molecules implicated in bone resorption (IL-6, IL-17 and RANK-L), was
demonstrated in AMD3100 treated, P. gingivalis- infected mice in contrast to infected
mice who received no treatment. AMD3100 treatment provided a protective effect
against development of destructive periodontal inflammation by preventing establishment
of P. gingivalis infection and the resultant increase in commensal flora.
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AMD3100 infusion effectively halts progression of periodontal bone loss two weeks
after induction of disease.

AMD3100 treatment resulted in eradication of P. gingivalis from the oral tissues and
protection from P. gingivalis-mediated bone loss in the context of prophylaxis (See
Figure 10), suggesting the drug could be an excellent candidate as a therapeutic agent in
periodontal disease. To test this hypothesis, mice were inoculated with 109 P. gingivalis
or sterile PBS as in previous oral infection model experiments. Two weeks after the final
inoculation mice were implanted with mini osmotic pumps designed to release drug for
two weeks containing 10 mg AMD3100 in 0.1 ml PBS or PBS only. On Day 60 mice
were euthanized to evaluate periodontal disease and host inflammatory status in the
gingival tissues. We elected to begin therapy two weeks after the final inoculation
because our group previously demonstrated that bone loss in P. gingivalis- infected mice
is statistically significant versus sham infected mice at that time. Two weeks into the oral
infection model corresponds theoretically to early stages of periodontal disease when
bone loss is not yet extensive. This stage of the oral infection model is a window in which
it would be maximally efficacious for patients already demonstrating disease to initiate
treatment.

Indeed, systemic AMD3100 therapy post induction of periodontal disease

halted progression of bone loss (See Figure 12). Some isolated pockets of bone loss were
noted in AMD3100 treated, P. gingivalis infected, mice, particularly around the third
molar (Figure 12) as bone resorption experienced in periodontitis is non-reversible (8)
(143). Overall, however, treated mice demonstrated significantly less alveolar bone loss
than untreated ice when challenged with P. gingivaiis, indicating an effective halt in
disease progression upon initiation of AMD3100 therapy (p< 0.01). Taken together the
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above studies indicate the P. gingivalis- CXCR4 interaction as a promising therapeutic
target and treatment with antagonists such as AMD31 00 as a possible strategy for halting
progression of periodontal disease.
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Figure 12. Therapeutic treatment with AMD3100 halts P. gingivalismediated periodontal bone loss. BALB/c mice (l0-12 weeks of age) were
orally infected with P. gingiva/is as described in Methods. Two weeks after the
last inoculation with P. gingivalis, the mice were administered AMD3100 (or
PBS control) via osmotic minipumps. Data are means ± SD (n = 5 mice per
group); negative values indicate bone loss in P. gingivalis-infected mice relative
to sham-infected controls.

** P

< 0.01 compared to control and all other

experimental or groups. AMD, AMD3100; Pg, P. gingivalis.

Discussion
It has recently been proposed that periodontitis fundamentally represents a

disruption of host microbe homeostasis in the periodontal tissue (46). This notion is
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supported by mechanistic studies in the mouse model of periodontitis: Alterations either
in the composition of the periodontal microbiota or in local regulatory mechanisms that
control leukocyte recruitment can cause disruption of periodontal homeostasis which, in
tum, may lead to uncontrolled inflammation and periodontal bone loss (97).
P. gingivalis benefits from modulating the inflammatory response. Through
interactions with several receptors and elements of the innate immunity P. gingivalis
selectively allows inflammation beneficial to its survival to carryon while other key
aspects of immunity are shut down. Induction of subversive crosstalk between innate
immune receptors seems to be a favorite mechanism of P. gingivalis. We have previously
shown that P. gingivalis induces inflammation via C5aR-TLR2 crosstalk which is likely
to cause collateral tissue damage (inflammatory periodontal bone destruction) (154). We
now demonstrate in a preclinical model that P. gingivalis participates in CXCR4
modulation of TLR2 antimicrobial signaling. P. gingivalis manipulates both sets of
receptors by inducing their collection into close physical proximity (103, 276), and as a
result TLR2-mediated antimicrobial signaling is inhibited. Perhaps P. gingivalis'
multifactorial attack upon TLR2 antimicrobial signaling betrays the important role of this
Toll-Like receptor to success of the pathogen.
Currently, there is an urgent need to develop innovative adjunctive therapeutic
strategies in chronic periodontitis (92). Indeed, conventional periodontal treatment is
often not sufficient by itself to treat destructive inflammation and, moreover, this oral
disease appears to increase the patients risk for atherosclerosis, diabetes, chronic
obstructive pulmonary disease, adverse pregnancy outcomes, and possibly rheumatoid
arthritis (80) (143) (159) (206) (261).
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One approach to treating periodontitis is to counteract immune evaSIOn or
subversion by major periodontal pathogens. Periodontal and other microbial pathogens
preferentially target and corrupt innate immunity (70) (96). Subversion of innate
immunity may additionally undermine the overall host defense, given the instructive role
of the innate response in the development of adaptive immunity (201). Therefore,
understanding the molecular mechanisms whereby microbial pathogens interact with and
exploit innate immune receptors may facilitate the development of intervention
approaches to inhibit immune evasion and disease pathogenesis.
In this study, I took advantage of our group's earlier findings that implicated
CXCR4 in P. gingivalis immune subversion (103) and showed that a CXCR4 antagonist
can protect against P. gingivalis-induced periodontal bone loss in both preventive and
therapeutic models. The expression of CXCR4 has been shown to be elevated in chronic
periodontitis compared to healthy gingiva (122) (126). However, it is uncertain whether
CXCR4 plays a role in periodontal pathogenesis. In this regard, the above study is the
first to causally link CXCR4 to periodontitis in a preclinical model. The protective effect
of AMD31 00 against P. gingivalis-induced periodontitis may be attributed, at least in
part, to the blockade of the host receptor, CXCR4, which is apparently important to
survival of P. gingivalis in the periodontium. This conclusion is based on the ability of
AMD3100 to enhance the killing of P. gingivalis by leukocytes (103) and, moreover, to
mediate its elimination from the periodontal tissue in vivo (this study).
The natural ligand for CXCR4 is the chemokine stromal cell-derived factor-l
(SDF-l), although CXCR4 also functions as a co-receptor with CD4 for the HIV-l
envelope gp120/gp41 complex (195). In this context, AMD3100, which can also potently
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antagonize human CXCR4 (106), was shown to block CXCR4-dependent HIV-l entry
and replication (49) (60). Moreover, AMD3100 can protect against several CXCR4mediated pathophysiological conditions, such as rheumatoid, infectious, allergic, and
malignant diseases, both in humans and in experimental mouse models (49) (113) (158,
168). This study adds periodontitis to the list of potential therapeutic applications of
AMD3100.
The ability of AMD3100 to inhibit periodontitis by apparently targeting P.
gingivalis (as this antagonist did not directly influence the periodontal microbiota) has a

theoretical basis on the keystone pathogen concept. According to this concept, P.
gingivalis- at low colonization levels- impairs innate immunity in ways that alter the

growth and development of the entire biofilm resulting in dysbiosis that triggers
periodontal disease, at least in the mouse model (97). On the other hand, neither the
indigenous murine microbiota alone, nor P. gingivalis by itself (i.e., in germ-free mice)
can initiate pathologic bone loss in young healthy mice (97). In the presence of
AMD3100, P. gingivalis failed in this study to support the overgrowth of the total
periodontal micro biota which is required for induction of periodontitis. AMD3100 was
effective against periodontitis even when the disease was already in progress, suggesting
that the continuous presence of P. gingivalis, albeit at very low levels compared to the
total bacterial counts, is strictly required to sustain dysbiosis and disease progression.
In humans, P. gingivalis is also a quantitatively minor component of
subgingival pathogenic biofilms, despite its high prevalence, and is associated with
progressive bone loss in periodontitis patients (38) (63) (138) (184) (184). It should be
noted that adult chronic periodontitis is associated with multiple etiologies and disease
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modifiers (93) (134) (143) (206) and, therefore, the presence of P. gingiva lis may be just
one of several etiologic factors. Nevertheless, under favorable environmental conditions,
this bacterium has the potential to act as a keystone pathogen to transform an otherwise
symbiotic micro biota into a dysbiotic microbial community that can cause periodontitis
(97).

In summary, my results establish a role for CXCR4 in P. gingivalis-induced
periodontitis and show that CXCR4 antagonism by AMD31 00 confers protection against
the disease through an antimicrobial effect. Given that AMD31 00 has been shown to be
safe in humans (227), this and other CXCR4 antagonists could find application as
adjunctive therapeutics for the treatment of human periodontitis.
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CHAPTER FOUR: CXCR4BLOCKADEENHANCESCLEARANCEOFR
GINGIVALIS

Introduction

The oral cavity is an impressive and elegant example of the ability of innate
immune cells to interact with a staggering number of constant commensal microbial
signals and still parse out the pathogenic signals among them. However, it is also a
critical example of the clinical repercussions of innate immunity gone wrong. In
periodontal disease, host immune signaling is hijacked by pathogens such as P.

gingivalis, causing specific repression of host immunity that would clear the bacteria,
while unproductive aspects of the response are allowed to proceed, such as the induction
of inflammatory and bone resorptive cytokines.
Gram-negative, anaerobic bacteria are typically the instigators of periodontal
disease, given opportunity to step beyond the boundaries of the commensal lifestyle by
poor oral hygiene, and the resulting tissue destruction can further provide a route of
invasion for oral pathogens beyond the gingival epithelium into the systemic circulation
and beyond. In this situation, bacterial products such as endotoxin can induce
inflammatory cytokine production in distal areas of the body to incite pathogenic
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processes, for example, atherosclerotic plaque formation and thrombogenesis (270) (249)
(277). Upon repeated challenge, local cytokine receptors within the periodontium can
become saturated, allowing cytokines to evade clearance and spill into the systemic
circulation (196, 277).
CXCR4

IS

a

G-protein-coupled

chemokine

receptor

possessmg

seven

transmembrane regions which specifically recognizes CXCL12 (SDF-l), although it is
recently shown that SDF -1 does not specifically interact with CXCR4 but also
demonstrates interaction with CXCR7. CXCR4 is found predominantly on leukocytes
and in response to SDF-l activates MAPKI/MAPK3 signaling by increasing intracellular
calcium ion levels. It has been recently shown that CXCR4 recognizes extracellular
ubiquitin as a natural agonist and in response to extracellular ubiquitin CXCR4 promotes
intracellular Ca(2+) flux and reduces cAMP levels in THPI cells (223).
CXCR4 is a co-receptor for CD4 to facilitate HIV entry into host cells and is
highly expressed on breast cancer cells. Mutations in CXCR4 have been associated with
WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome.
In addition to mediating chemotaxis of immune cells such as monocytes and T
cells , SDF -1 can be found on stromal cells of the bone marrow, which constitutively
express the CXC chemokine(187) (22, 29).

Here SDF -1 plays a critical role in cell

survival, proliferation, directed migration, and engraftment (3, 4, 146, 155, 178). CXCR4,
consequently, is expressed upon hematopoietic progenitor cells and these cells are
anchored into the stroma via the CXCR4-SDF-l interaction (3, 178). Since this anchoring
is reliant upon the SDF -CXCR4 interaction, AMD3100 was discovered to interrupt and
mobilize these progenitors, notably CD34+ hematopoietic progenitor cells (116).
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Gene deletion of CXCR4 or SDF-1 leads to perinatal death in mice, the animals
succumbing to hematopoietic, cardiac, gastrointestinal and cerebellar abnormalities (188)
(160). However, mice in which the genes are conditionally knocked out after the critical
development window survive and can be used for studies involving the role of CXCR4SDF-l. We hypothesized that, although AMD3100 acts as an agonist upon CXCR7,
CXCR4 was more likely to be the functional target causing protection from periodontitis
as P. gingivalis is known to interact with CXCR4. The CXCR4 conditional knock out
mice used in our study were developed on a B6 background using beta-actin-cre to select
and knockout all or most ofCXCR4.
Previously it was shown in come cancer lines, among them squamous cell
carcinoma, that osteoblasts can produce SDF-1 and that this expression can induce IL-6
production. AMD3100 inhibited this SDF -1 induced IL-6 expression (252). While these
results were found in an abnormal cell line we wondered whether SDF-1 signaling could
play any, albeit a secondary, role in P. gingivalis infection. It could be that P. gingivalis
acts as a surrogate SDF-1-like signal, inducing IL-6 expression through activation ofNF-

KB. We therefore assayed several inflammatory cytokines such as IL-6 and TNF -u to
track the effect of CXCR4 deficiency in mice which were sham and P. gingivalis
infected.
While RT-PCR has increasingly become a reliable and, in P .gingivalis' case in
the Baker oral model, necessary method of detecting and quantifying bacteria, we wanted
to know more about the kinetics of the AMD3100 effect on P. gingivalis, as well as to
show definitively that AMD31 00 is quickly lethal to the pathogen. Therefore we decided
to use the subcutaneous chamber model to determine in vivo bacterial viability in the
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presence of the compound and to look at how AMD3100 treatment changes to host
dynamic in a microaerophilic space representative of the deep gingival pocket (79). The
chamber itself is a titanium coil which is implanted subcutaneously dorsolateral of the
mid-spine. The coil becomes encapsulated by connective tissue, creating a hypoxic
interior lumen (85). This experimental scenario allows for studying the interactions
between bacteria, compounds, and the host response in a close, temporal way. Since
cytokines, host cell influx and viable bacterial counts can all be taken from the chamber,
one can tell exactly what the host immune response less than an hour after introduction of
the bacteria (30, 85, 175). Therefore this model was ideal to confirm our hypothesis that
CXCR4 blockade with AMD3100 leads to a quick elimination of P. gingivalis by the
host.
Deficiency in other receptors involved in P. gingival is-mediated subversive
crosstalk (C5aR, TLR2, CR3), protects against periodontal bone loss. Use of C5aRdeficient mice elucidated the role of C5aR signaling in P .gingivalis immune evasion,
including the induction of hallmark inflammatory cytokines in periodontal destruction
(82) (154). CR3 was likewise shown to be an exploited receptor by P. gingivalis using
CR3-deficient mice (94). CR3 was necessary for survival of P. gingivalis in a peritoneal
lavage model, along with reduction in Il-12p70 and IFN-y levels.
With these studies we sought to confirm the specific role of CXCR4 in
periodontal disease induction by P. gingivalis. We show that CXCR4 deficiency indeed
changes the dynamic of the host response to P. gingivalis, though attempts to discern
whether this effect is necessarily protective were initially mixed. We show that the
overall cytokine profile of CXCR4 deficient mice infected with P. gingivalis is largely
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comparable to that of P. gingivalis-infected mice treated with AMD3100. We also show
using the subcutaneous chamber model that AMD3100 treatment induces a stronger,
targeted immune response to P. gingival is, necessitating accelerated clearance of the
pathogen by two hours post inoculation. No effect was observed when AMD31 00 was
co-injected with a fellow gram negative oral anaerobe of P. gingivalis, F nucleatum.
Viable bacterial counts of F nucleatum were unaffected, showing that the effect of
AMD3100 on viability is at least to some extent specific to P. gingivalis, for F

nucleatum is a bacterium which, given its location and relationship to P. gingivalis,

IS

highly likely to be affected by non-specific treatments targeting P. gingivalis.

Results
AMD3100 inhibits P. gingivalis-induced PMN recruitment but promotes
killing of P. gingivalis. Systemic treatment with AMD31 00 prevents periodontal disease
in a prophylactic context and halts disease progression in mice when administered
therapeutically and according to the PCR data likely leads to eradication of the pathogen.
However, direct culture of P. gingivalis is generally impractical from the Baker Model so
we decided to use the subcutaneous chamber model to gain a more mechanistic insight as
to the effect of AMD3100 administration specifically on P. gingivalis survival and
leukocyte migration to the site of infection. To this end we employed the subcutaneous
chamber model to test P. gingivalis viability with AMD3100 treatment. As a baseline
control for cytokine analysis and to assure sterility of the chambers prior to P. gingivalis
inoculation we drew chamber exudates immediately prior to infection. We diluted and
plated these exudates for CFU and analyzed them for key cytokines using EIA and
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Luminex. The actual destruction associated with periodontal disease is caused by
uncoupled osteoclastogenesis in response to constantly infiltrating leukocytes (86),
therefore we additionally quantified leukocyte infiltration into the chamber to determine
if AMD31 00' s efficacy could be attributable to its effect on leukocyte trafficking.
We found that concurrent AMD31 00 treatment with inoculation of P. gingivalis
leads to a ten-fold enhancement of P. gingivalis killing at 2 hours post injection and over
a hundred fold increase in killing by 24 hours (See figure 13). We also found that,
although AMD31 00 promotes P. gingivalis killing, it inhibits leukocyte recruitment into
the subcutaneous chamber. However, when AMD31 00 is injected alone into chambers it
induces a moderate amount of leukocyte recruitment, ostensibly due to its effects on
granulocyte precursor and CD34+ HSPC emigration from the bone marrow.
Inhibition of intracellular crosstalk pathways instigated by P. gingivalis enhances
the ability of the host immune system to eradicate the pathogen. We, therefore, reasoned
that CXCR4 blockade must reduce P. gingivalis' ability to subvert TLR2 mediated
inflammation, leading to increased efficiency of neutrophil uptake/killing of the bacteria
in the chamber at the earlier time-point and therefore less recruitment signal at the later
time-point corresponding with the significantly lower number of viable bacteria.
Taken together, these data suggest that AMD3100 treatment leads to enhanced
killing of P. gingivalis early in infection by enhancing the ability of recruited leukocytes
to rapidly clear the infection through TLR2 mediated antimicrobial inflammation. A
product of this efficiency is lowered PMN recruitment probably due to chemotactic
signals indicating successful reduction of infection.
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Figure 13. AMD3100 inhibits P. gingivalis-induced PMN recruitment but
promotes killing of P. gingivalis. BALB/c mice (10-12 weeks of age) were
implanted with titanium coil chambers subcutaneously. After a ten day healing
period, exudates were drawn from the titanium chambers to verify sterility prior to
experimental infection as well as analyze baseline amounts of leukocytes and
inflammatory markers. Mice were infected or treated as described in Methods. The
mice were euthanised 24 hours after injection. Exudates were plated for P.
gingivalis CFUs and leukocytes were counted using a hemocytometer. Data are

means ± SD (n

=

5 mice per group). **p < 0.01 compared to control and all other

experimental groups. AMD, AMD3100; Pg, P. gingivalis.
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AMD3100 does not affect F. nucleatum-induced PMN recruitment or F. nucleatum
killing. Systemic administration of AMD31 00 causes a transient leukocytosis. General as

it is, the leukocytosis is comprised predominantly of circulating neutrophils (155). This,
coupled with our data indicating the enhanced killing resultant of co-AMD3100
administration in the chamber model, made us wonder if we were observing a trend
generally true for all bacteria. Specifically, greater numbers of roaming granulocytes
throughout the body may pose a greater threat to any bacteria placed within the chamber.
To test this hypothesis we inoculated subcutaneous chambers with F nucleatum either
co-injected with sterile PBS or AMD31 00.
We found that, while F nucleatum generally does not survive the subcutaneous
chamber as well as P. gingivalis, AMD3100 co-treatment had no significant effect on
viable F nucleatum recovery from chambers (See Figure 14). We also noted that
leukocyte recruitment in F nucleatum AMD3100 treated chambers was similar to
recruitment in AMD31 00 treatment alone or P. gingivalis and AMD31 00 injected mice
compared to their corresponding baseline leukocyte counts.
Taken together, these data indicate that AMD3100 does not affect other gram
negative oral anaerobes and that the observed clearance of P. gingivalis is probably due
to uncoupling of the subversive CXCR4-TLR2 crosstalk. With TLR2 more able to
initiate the appropriate downstream inflammatory pathways, infiltrating neutrophils can
clear the pathogen more efficiently, leading to a decreased recruitment of neutrophils into
the infected area.
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Figure 14. AMD3100 does not significantly affect F. nucleatum-induced
PMN recruitment or F. nucleatum killing. BALB/c mice (10-12 weeks of age)
were implanted with titanium coil chambers subcutaneously. Exudates were
drawn from the titanium chambers to verify sterility prior to experimental
infection as well as analyze baseline amounts of leukocytes and inflammatory
markers. Mice were infected or treated as described in Methods. The mice were
euthanised 24 hours after the inoculation/treatment. Exudates were plated for F
nucleatum CFUs and leukocytes were counted using a hemocytometer. Data are

means ± SD (n = 5 mice per group).

**p < 0.01

compared to control and all other

experimental groups. AMD, AMD31 00; Fn, F nucleatum.

Host Response to treatment with AMD3100 in the subcutaneous chamber model
We decided to look more closely at the cytokine response within the subcutaneous
chamber model in response to P. gingivalis infection and AMD3100 treatment. We
observed a slight increase in TNF -u production in response to P. gingivalis infection as
compared to baseline controls. AMD3100 treatment alone did not elicit a TNF-u
response, however, after repeated analysis of chamber exudates using the Luminex Bead
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Assay, we observed a reliably significant synergistic increase in TNF-a at two hours post
injection in mice infected with P. gingivalis and injected with AMD31 00, corresponding
to an allowance of the TLR2 NF-KB antimicrobial pathway activation. While AMD3100
treatment alone induced production of IL-6 in the chamber nearly ten fold beyond the
amount of IL-6 found in the baseline samples, P. gingivalis infection caused an over ten
fold decrease of IL-6 in the chamber and co-injection of AMD31 00 with P. gingivalis
into chambers did not cause a significant change in IL-6, an interesting reversal of our
RT-PCR findings in the gingivae of orally infected mice. As opposed to our RT-PCR
findings in the chronic oral infection model, these findings at two hours post infection in
the subcutaneous chamber model indicate AMD31 00 treatment doesn't change the effect
of P. gingivalis on IL-6 levels, but does cause a productive increase in TNF-a.
Additionally we noted an approximately two fold increase of IL-l 0 in mice injected with
both the pathogen and compound as compared to P. gingivalis infected mice (See Figure
15).
MIP-la and M-CSF were also increased in AMD3100 treated, P. gingivalis
infected mice at two hours compared to mice infected alone. The increase in Mip-l a
indicates an increase in immediate inflammation in response to the pathogen and possibly
an induction of superoxide production by neutrophils, one of the leukocyte'S best
weapons against P. gingivalis infection (235). Increases in M-CSF, though transient,
could be an indicator of AMD3100's effect on CXCR4 signaling, as increased
intracellular levels of cAMP inhibit the synthesis of M-CSF and CXCR4 blockade should
inhibit cAMP-dependent PKA signaling (l03) (292). M-CSF production indicates
progression of the inflammatory process and the host direction of monocyte
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differentiation into macrophages and macrophage chemotaxis to the infected area. Our
data show, compared to mice with subcutaneous chamber implants inoculated with P.
gingivalis alone, that
TNF-a

IL-1 P
IIIIIiIIII baseline
[]II] AMD3100

00 pg alone

§

IL-6

+ 2.5 119 AMD3100

IL-10

*

Figure 15. AMD3100 treatment increases TNF-a and IL-I0, indicating a more
appropriate antimicrobial response to the presence of P. gingivalis. BALB/c

mice (l0-12 weeks of age) were implanted with titanium coil chambers
subcutaneously. After a ten day healing period, exudates were withdrawn and were
analyzed for cytokines.

Supernatants were analyzed with the Luminex-

100/multiplex cytokine analysis system (Upstate). Data are means ± SD (n = 5
mice per group). *P < 0.05 compared to control or indicated experimental groups.
AMD, AMD3100; Pg, P. gingivalis.
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Figure 16. AMD3100 treatment leads to an ultimate suppression of MIP-1a,
indicating a resolution of inflammation, decreased superoxide release by
neutrophils. BALB/c mice (10-12 weeks of age) were implanted with titanium
coil chambers subcutaneously. After a ten day healing period, exudates were
withdrawn and were analyzed for cytokines. Supernatants were analyzed with the
Luminex-100/multiplex cytokine analysis system (Upstate). Data are means ± SD
(n = 5 mice per group). *p < 0.01 compared to indicated experimental groups.

AMD, AMD3100; Pg, P. gingivalis.

co-injection of AMD31 00, along with enhanced eradication of the bacteria, causes a
decrease in Mip-1 a correspondent with clearance of the bacteria by 24 hours (See Figure
16). Thus the increases in these inflammatory markers are only transient in AMD3100
injected mice and demonstrate an initiation of productive inflammation resolution, as the
viable bacteria numbers are being eradicated. Taken together, our observations gleaned
from the subcutaneous chamber model indicate that the host response is enabled by the
blockade of CXCR4 very early in P. gingivalis infection, allowing the host to proceed
with a productive inflammatory response that works effectively to clear the pathogen.
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Deficiency of CXCR4 or TLR2 differentially affects the inflammatory response to P.
gingivalis infection in mice.

P. gingivalis-fimbriae interact directly with CXCR4 to interfere with TLR2mediated NF-KB signaling. This in tum causes a down-regulation of inflammatory
mediators such as TNF-a, IL-6 and up-regulation of anti-inflammatory IL-I0 (103) in
mouse macrophages/human monocytes. AMD3100 treatment prevents this interaction
and subsequently protects the host against P. gingivalis-mediated periodontal disease
(Figures 10-13).
Deficiency of TLR2 was previously shown in both C57 B6 mice(30) and
Balb/c mice (154) to be protective against P. gingivaZis mediated bone loss. This, coupled
with the knowledge that AMD3100 treatment halts bone loss, led us to question if
deficiency of CXCR4 would likewise demonstrate protection against P. gingivalis.
We tested the ability of P. gingivalis to initiate bone destruction in CXCR4
conditional knockout mice compared to their wild-type counterparts. CXCR4-deficient
mice die perinatally and so their use in in vivo periodontitis models is precluded. We
verified successful deletion of CXCR4 in periodontal tissues via RT-PCR (See Figure
18). We infected each group with P. gingivalis or vehicle 5 times and euthanized mice
on day 60.
The effect of P. gingivalis infection upon alveolar bone in CXCR4 knockout mice
compared to corresponding wild-types was inconclusive (See Figure 17A) perhaps due to
the small size of each group. Both infected and sham-infected CXCR4 deficient mice did,
however, demonstrated elevated transcriptional levels of several inflammatory molecules,
albeit to various degrees.
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As in mice administered AMD3100 for several days, mRNA levels for
inflammatory cytokines in the gingivae were elevated in CXCR4 deficient, sham-infected
mice.

This indicates the

importance of CXCR4

signaling in regulation of

proinflammatory cytokine expression, however given these mice did not suffer bone loss,
high mRNA levels of inflammatory cytokines alone is not indicative of disease. TNF-u
and RANK-L were most notably down regulated in CXCR4 deficient, P. gingivalisinfected mice as compared to their wildtype counterparts. These data agree fundamentally
with our previous data showing P. gingivalis induces crosstalk between TLR2 and
CXCR4 to inhibit TLR2-mediated inflammation (103).
CXCR4 deficient mice, while not suffering the extent of periodontal bone loss
seen in their wild-type counterparts, did demonstrate a trend of inflammatory
upregulation as compared to the downregulatory trend noted in TLR2 deficient mice.
The enhanced ability of the host to quickly eliminate P. gingivalis when it cannot
recognize CXCR4 is more important than the ability to modulate inflammation over a
longer period of time.
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Discussion

In this study we addressed whether CXCR4 blockade has a direct benefit in
controlling P. gingivalis infection in the chamber model. We found that recognition of
CXCR4 by P. gingivalis indeed plays an integral part in ability of the pathogen to survive
in the oral cavity. Blockade of this recognition led to clearance of the pathogen and
consequent halt to bone resorption in both preventative and therapeutic context.
This effect was shown to be specific at least to a certain degree as AMD3100
treatment had no survival effect upon F nucleatum, a gram negative member of the
"orange complex" oral bacteria. Like our data at earlier time-points in the oral model of
infection, in the subcutaneous chamber we saw higher protein levels of TNF -u in
response to AMD3100 injection with P. gingivalis. These findings indicate strongly that
TLR2 antimicrobial signaling is restored upon blockade of CXCR4.
In the absence of CXCR4 signaling in the chamber model we noted that, as
opposed to the oral infection model, at two hours post injection AMD31 00 treatment did
not effect P. gingivalis repression of 11-6 levels below the baseline level. This suggests
that effects of IL-6 in the oral infection model are either temporal in nature, perhaps
driving later inflammatory damage, or is an outcome of chronically dysregulated P.
gingivalis-induced inflammation, perhaps via dysregulation of SOCS3 feedback

inhibition. It is worthy to note that 11-6 protein levels are elevated in chamber baseline
exudates as compared to the gingivae tissues, such that the dynamics of IL-6 feedback
regulation are different in the chamber versus the oral cavity.
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Regarding our host response data from the chamber model, Nakajima and
coworkers

in

their

report

"Periodontitis-associated

up-regulation

of systemic

inflammatory mediator level may increase the risk of coronary heart disease" showed that
patients with periodontal disease have increased levels of IL-6 but decreased levels of
TNF -a and our chamber model results reflect these established observations in humans.
TNF-a has been described as a more "protective" cytokine regarding early periodontal
inflammation as opposed to IL-6, which, when upregulated, generally corresponds to
uncoupled inflammatory periodontal destruction. It is important to remember, however,
that without some appropriate inflammation, the host will fail to clear the bacteria and
disease will manifest due simply to chronic infection. Therefore inflammation has to
happen in order to clear the pathogen, but it must be appropriate and carefully regulated.
Specific subversion by P. gingivalis of TLR2 via crosstalk with other receptors plays a
critical role in throwing the inflammatory response out of balance (86) (9) (11, 39) (115)
(53, 76).
Since Mip-la is a strong chemoattractant of both monocytes and T cells, we
interpreted the decrease of this cytokine by 24 hours in P. gingival is infected, AMD31 00
treated mice as an indicator of enhanced resolution of the infection. P. gingivalis-infected
mice showed no reduction in Mip-la levels relative to infected mice co-injected with
AMD3100 by 24 hours (254) (140). It is worthy to note that Mip-l a is also a proosteoclastogenesis cytokine the induction of which helps in the maturity of osteoclastprecursors into functional osteoclasts (239). Along with the other key pro inflammatory
cytokines involved with the periodontal disease process, macrophage colony stimulating
factor and MCP-l are both involved with regulation of bone metabolism. M-CSF
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contributes to activation and differentiation of quiescent osteoclasts. The functions of
these cytokines make them useful in determining how theoretically prone to bone
destruction the subcutaneous chamber environment becomes in response to infection or
treatment. Both these molecules are decreased significantly in response to AMD3100
treatment in infected mice from oral infection or chamber model experiments, suggesting
that AMD31 00 treatment, through enhancing host clearance of the bacteria, ameliorates
conditions leading to uncoupling the resorption/regeneration balance within the alveolar
bone (226).
To address the sometimes increased levels of TNF-a in both our gingivae RTPCR as well as the chamber exudates, it is useful to consider the philosophy reviewed by
Graves and coworkers that induced TNF-a in gingivitis is actually protective as blocking
the cytokine leads to increased bone loss (39) (76, 86). The overall message to take from
these results which seemingly contradict common reason is that oral health is a sort of
homeostasis in which the amount of microbe-induced inflammation is not too extensive,
but also not too gentle. If the microflora is not kept in check, a pathogenic shift in the oral
biofilm becomes increasingly likely, but if the inflammatory response is overly abundant,
the host homeostasis is disrupted, notably the coupling of bone resorption and
restructuring. In the situation of a chronic, non-productive, highly chemotactic
inflammation, resorptive signals and processes outrun the restorative processes and
periodontitis is the result (86).
The distinct and arguably proinflammatory profile caused by long term systemic
AMD3100 administration was paralleled in conditional CXCR4 KO mice. We observed
upregulation of several proinflammatory genes with no corresponding bone loss in sham
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infected mice. CXCR4 deficient mice have elevated amounts of inflammatory molecules
in their gingivae as compared to TLR2 deficient mice. While the difference in
background of these two knockout mice precludes a direct comparison of their respective
immune responses, in the context of comparing differences in gene expression between
uninfected mice and P. gingivalis infected mice, CXCR4 deficient mice seem more prone
to inflammation, based on the RT-PCR data of inflammatory cytokines. While these mice
do not demonstrate an accelerated loss of alveolar bone, inflammation in CXCR4 KO
mice appears to be more easily triggered due to the receptors functional loss, showing
that perhaps there are two opposing mechanisms at work. Primarily, the beneficial effect
of blocking P. gingivalis- CXCR4 interaction through removal of the receptor should
enhance killing of the pathogen as in AMD31 00 treated mice. However, in mice which
do not possess a functional CXCR4 at all, the pro-inflammatory

NF-K~

mediated

pathway is apparently non-specifically activated (See Figure 18A).These findings are
also compatible with other findings regarding AMD3100, CXCR4 and inflammatory
modulation, among them murine osteolytic tumor models wherein short term
administration of AMD31 00 causes increased neutrophil mobilization without effecting
bone resorption (112).
CXCR4 deficient mice showed mixed results regarding protection from P.

gingivalis induced bone loss, however, the inflammatory profile of CXCR4 deficient
mice reflected nicely the differential expression observed in mice systemically
administered AMD31 00 for extended periods of time. As in the AMD31 00 treated mice,
transcript levels of several pro-inflammatory cytokines as well as bone resorptive
molecule transcripts are upregulated. However, sham-infected CXCR4 deficient mice
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demonstrate absolutely no bone loss despite an apparent inflammatory state. RANK-L
and TNF-a were downregulated in CXCR4 deficient mice infected with P. gingivalis as
compared to infected wild-type mice. Even though the bone loss data were largely
inconclusive, the differential expression of inflammatory markers indicate the importance
of CXCR4 signaling in P. gingivalis- mediated periodontal disease.
Lee and coworkers showed direct activation of granulocytes by AMD3100 and
consequent activation of C5 by these granulocytes in the peripheral blood (149). These
observations has led us very recently to wonder whether the in vivo protective effects we
observed in AMD31 00 treated mice were in fact due to CXCR4 blockade or perhaps to
enhanced peripheral C5 cleavage by granulocytes to counter other subversive strategies
widely documented to be used by P. gingivalis. One question that remains is whether a
local administration of AMD31 00 into the oral cavity would have comparable therapeutic
advantages while bypassing the transient HPSC mobilization seen with systemic
treatment.
P. gingivalis selectively suppresses and induces periodontal inflammation to its

own benefit. P .gingiva/is recognizes TLR2, CXCR4, TLR4 as well as C5aR and CR3.
TIR2 subversion, however, has been revealed as a recurrent theme amoung the tactics
employed by P. gingivalis to avoid elimination by the host immune response. P.
gingiva/is induces co-association and crosstalk between receptors of its choosing to

suppress anti-microbial signaling and also to upregulate destructive, untargeted collateral
periodontal tissue damage. In these studies we demonstrated that P. gingivalis-induced
CXCR4 modulation of TLR2 antimicrobial signaling is a crucial method to the pathogen.

P. gingivalis induces co-association of CXCR4, TLR2 as well as CD14 into close
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physical proximity (103, 276) and as a result TLR2-mediated antimicrobial signaling is
inhibited CXCR4 instigated cAMP mediated PKA signaling (See Figure 19).
In conclusion, we showed that when P. gingivalis is unable to incite subversive
crosstalk between CXCR4 and TLR2 mice are protected from periodontal bone loss and
furthermore that P. gingivalis is not detectable at day 7 of infection after AMD3100
treatment. The host response in these mice reflects a differential expression of
inflammatory cytokines and markers. Mice solely infected with P. gingivalis demonstrate
a broad uncontrolled inflammation that is a hallmark of chronic progressive periodontal
destruction. In contrast, mice that are treated with the CXCR4 antagonist in addition to P.
gingivalis infection display at earlier time-points a different inflammatory response, and

at later time-points indicate resolution of inflammation.
However, P. gingivalis also relies upon its ability to subvert complementmediated killing as well as resistance of oxidative killing by neutrophils. AMD3100 has
been shown to enhance both egress of neutrophils into the circulation as well as their
noncanonical cleavage of C5 (149). This cleavage of C5 could in turn, prime neutrophils
in the circulation prior to their influx into the periodontium. This priming, if it occurs,
would give incoming neutrophils an advantage in taking up and clearing P. gingivalis.
Both these outcomes could supplement the protective effect of CXCR4 blockade targeted
with long term systemic AMD31 00 treatment. Also, it has been recently discovered that
AMD3100 is a partial agonist of CXCR7 (123).
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Figure 19. AMD3100 in the chronic P. gingiva/is periodontitis model. In
macrophages, P. gingivalis interacts with the CD 14/TLR2/TLR 1 receptor
complex (99). Upon C5aR binding, C5a stimulates Gai-dependent intracellular
Ca2+ signaling which synergistically enhances the otherwise weak cAMP
responses induced by TLR2/TLRl activation alone. Maximal cAMP induction is
achieved by the participation of another G protein coupled receptor, the CXCR4,
which interacts directly with P. gingiva lis and co-associates with both TLR2 and
C5aR in lipid rafts (103) (275). The ensuing activation of the cAMP-dependent
protein kinase A (PKA) pathway inactivates glycogen synthase kinase-3p
(GSK3P) and impairs the inducible nitrogen synthase (iNOS)-dependent killing of
the pathogen in macrophages in vitro and in vivo (275). AMD3100 prevents P.
gingivalis from interacting with CXCR4 and ever initiating this cascade of events.
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While it is still uncertain whether there are other, collateral mechanisms by which
AMD3100 protects against periodontal bone loss mediated by P. gingivalis, we have
shown that CXCR4 blockade, and the subsequent abrogation of pathogen instigated
CXCR4-TLR2 crosstalk, renders mice protected from periodontal bone destruction in
both a prophylactic and therapeutic context.
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CHAPTER FIVE: FUTURE DIRECTIONS

There is persisting necessity for innovative therapeutic strategies regarding
chronic periodontal disease, and an integral step to developing those strategies

IS

identification of specific mechanisms used by periodontal pathogens to subvert the host
immunity. Our studies have demonstrated a key role for CXCR4 in disease pathogenesis
involving P. gingivalis in the oral cavity. P. gingivalis interacts directly with CXCR4 via
its fimbriae to induce functional TLR2/CXCR4 co-association in lipid rafts. A cross-talk
then ensues between the receptor pathways which results in a cAMP dependent PKA
signaling that inhibits TLR2 induced NF -Jd3 activation (See Figure 19). It was initially
hypothesized that these events were solely responsible for CXCR4's benefit to P.
gingivalis. During the ensuing in vivo experiments, however, other possibilities have

come to light in addition to this evidence that P .gingivalis depends upon its fimbriae to
mediate immune evasion.

Therapeutic benefit of Local AMD3100 administration?

We have demonstrated a therapeutic advantage to AMD31 00 administration on a
systemic scale, showing that when AMD3100 is administered via osmotic pump to the
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entire body for several days, P. gingivalis mediated bone loss is haIted. We also showed
that local injection of AMD3100 into the gingivae just prior to infection with P.
gingivalis prevents inflammation of the periodontium. Taken with the other data
presented above, the prevention of this inflammation and neutrophil chemotaxis is
indicative of P. gingivalis being cleared from the infected site and bone loss should not
happen. However, this remains to be proven in a therapeutic setting. It would be valuable
to observe the effect of local administration of AMD31 00 after induction of alveolar bone
loss in mice. Since CXCR4 blockade has unrelated, unnecessary effects to the body
systemically it would be vastly preferable to minimalize the physiological area of contact
to the drug.
Should microinjection of AMD31 00 haIt development of alveolar bone loss in
response to chronic P. gingivalis infection then other, less invasive methods of local
administration could be considered. Perhaps AMD31 00 application could accompany the
scaling and root planing that is the current standard of care for patients with periodontitis.

CXCR7 and AMD3100, relevance to our model?
The recent discovery that AMD3100 acts as a partial agonist to CXCR7, and the
relative uncertainty of the CXCR7 receptors activity or relevance to periodontal disease
processes, has led us to wonder whether agonism ofCXCR7 by AMD3100 has any effect
on disease' progress, especially considering the finding that CXCR4 and 7 form
heterodimers

and

thus

effect

CXCL12

signaling

(190).

Considering

the

heterodimerization of the two chemokine receptors and the known agonism ofCXCR7 by
AMD3100, any effect of the chemokine receptor on periodontal infection would likely be
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in response to the compound. Whether such a theoretical effect runs counter to clearance
of the pathogen or actually works to enhance the action of AMD31 00 remains to be
investigated.

Role of granulocyte mobilizations, priming and CS in response to AMD3100
treatment?

We showed using CXCR4 conditional knockout mice that CXCR4 signaling is
important to modulation of inflammation in these mice independent of periodontal
disease. As stated above, subcutaneous injection of AMD3100 in normal human
volunteers at a dose of 80

~g/kg

causes granulocytosis immediately followed by

mobilization of CD34+ HPSCs into the circulation. This is in tum followed by direct
activation of complement (147) (116, ISS) and the complement cascade contributes to
regulation of HSPC egress from the bone marrow (212). CS has been identified as
arguably the most important component of the complement cascade to this process (149).
The previously observed activation of CS by these granulocytes in the peripheral blood
(148) raises the possibility that the in vivo protective effects we observed in AMD31 00
treated mice were in fact due to CXCR4 blockade or enhanced peripheral CS activation
by granulocytes before P. gingivalis has a chance to degrade the complement component.
In response to AMD31 00 treatment circulating neutrophils were reported to enhance CS
activation. It isn't unreasonable to think neutrophils could be primed in this way before
they reach the periodontium, directly resulting in enhanced clearance of the bacteria. In
principle, however, this could also lead to more inflammation and more bone loss if the
neutrophils do not evacuate the periodontium once the bacteria are neutralized. The

8S

"coupling" theory of bone remodeling addresses this concern to an extent. Even if the
host does suffer inflammation and tissue damage during the transient infection, there is
also a greater possibility that the host will recover as the periodontal infection has now
been changed from a chronic to acute process.

AMD3100 treatment and osteoclastogenesis

CXCR4 is an osteoclastogenic factor in addition to regulating chemotaxis, so it is
possible that blocking CXCR4 with AMD3100 could reduce bone resorption
independently of the inhibited Pg-CXCR4 interaction. Multiple myeloma plasma cells
produce significantly increased amounts of SDF-l a correlating with the presence of
radiological bone lesions in patients. When SDF-l a is added to an in vitro osteoclastpotentiating culture system the number and size of bone resorption lacunae are increased
and there is an increase in osteoclast activation related genes like RANK-L, and these
findings were reversed upon addition of a small-molecule CXCR4 inhibitor (289). A
separate study of oral squamous cell carcinoma cells showed that SDF-l a increased the
secretion of IL-6 in an ERK-dependent way, enhancing the downstream binding of p65
and p50 to the NF-KB element on the IL-6 promoter. This indicates a potential second
role of SDF-l in alveolar bone loss. Inhibition of CXCR4 prevented this reaction as well
(252).
However, our RT-PCR of gingivae infected with P. gingivalis does not confirm
this hypothesis as IL-6 and its feedback regulators are not down or up regulated as
consistently as we would expect were this true. Therefore, more studies would be needed
to confirm or disprove this hypothesis.
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Conversely, CXCR4 has been sho\\TI in vivo to participate in osteoclast formation.
CXCR4 -I-mice generated by lethal irradiation and fetal liver transplant displayed
enhanced osteoclastogenesis and increased precursor proliferation and differentiation.
Enhanced tumor growth in bone but not in lung or small cell cancers was noted in the
CXCR4 -1- mice compared to equivalent wildtypes and the authors used the OC inhibitor,
zoledronic acid to reverse these effects. They proposed that these observation indicate
that inhibition of CXCR4 can actually enhance osteoclastogenesis at least in the in vivo
context of tumor metastasis to bone (111). The ligature model could be used to discern
which of the above statements is true regarding CXCR4 and periodontal bone resorption.
In the ligature model, sterile silk ligatures are pretreated either with vehicle or the
experimental compound, in this case AMD31 00, and tied around the right maxillary first
molar. The left maxillary first molar is left alone to serve as a control for each mouse.
Placement of the ligature alone causes some inflammation and bone loss due to
accumulation of bacteria, however if AMD31 00 treatment protects against inflammation
in and of itself, mice bearing the ligature and AMD31 00 should show less bone loss than
their untreated counterparts (130).

CXCR4 blockade, SDF-l and inflammation?

We have sho\\TI that CXCR4 blockade with an antagonist prevents periodontal
disease. The antagonist used for these studies, AMD3100, is an allosteric antagonist
blocking SDF-1 also from binding CXCR4, therefore, not only is P. gingivalis unable to
interact with CXCR4, neither is SDF-l. This means that, while we are inhibiting the
TLR2 crosstalk pathway, we are also inhibiting any homing or chemoattraction signals P.

87

gingivalis might attempt to induce host cells to produce via the CXCR4-SDF-I signaling
aXIS.

Since CXCR4 plays a role in P. gingivalis-mediated periodontal disease
pathogenesis, and AMD3l 00 treatment ameliorates this effect, it is reasonable to wonder
about any role the natural ligand of CXCR4, SDF -1, might play in disease pathogenesis,
especially in light of the fact that CXCR7 is allosterically agonized by AMD3l00 and
does have a binding capacity for SDF-l (13).
While it is possible that SDF-l signaling has its own importance to periodontal
bone loss, we think, rather, that the effect of blocking P. gingivalis-fimbriae signaling
through CXCR4 is specifically the cause of AMD3l00's amelioration of periodontal
bone loss and that SDF-l deficiency would not prove protective. P. gingivalis expressing
fimbriae lacking the "minor" fimbrial components FimCDE fails to interact with CXCR4,
precluding the ability of the bacteria to exploit the receptor. While strains such as JI-l
(nonfimbriated), OZ SOOlC (DAP) or K04 (DAP) which lack part or all of their fimbriae
cannot manipulate CXCR4 to promote their survival, it's very likely that all subtypes of
P. gingivalis possessing fimbriae that are the same or structurally similar have some

ability to use CXCR4 to promote their survival (205).
Inhibition of the interaction between CXCR4 and P. gingivalis fimbriae allows
the host immune response to eliminate the pathogen by appropriate regulation of
inflammatory cytokines such as IL-6 and TNF -u. Without downstream inhibitory
crosstalk between CXCR4 and TLR2, the balance is tipped in favor of the host and P.
gingivalis cannot create the permissive niche it requires to survive in the oral cavity,

making CXCR4 a critical co-receptor for P. gingivalis mediated pathogenesis. These
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assertions don't invalidate the pursuit of the question whether SDF-l is involved,
however, due to the ligands close association with CXCR4. There is a possibility that
SDF-l deficiency would reveal unforeseen effects upon periodontal bone loss.
It is possible that P. gingivalis uses CXCR4 as a homing device without which

leukocytes are not chemoattracted to the site of infection. It would be of interest to
determine the role of SDF-I-CXCR4 signaling in AMD3100 treatment of periodontal
disease. Perhaps constant stimulation of CXCR4 by P. gingivalis fimbriae contributes to
the constant and non-productive influx of neutrophils which is a hallmark of chronic
periodontal disease. Further experiments focusing on SDF -1 signaling could elucidate
any anti-microbial effect seen as a result ofCXCR4-SDF-l signaling blockade as well as
potentially contribute to our understand as to why, in the chamber model of infection,
AMD3100 injection alone and P. gingivalis inoculation both induce leukocyte
recruitment into the chamber but when the two are co-injected, leukocyte recruitment
appears to be attenuated.

The polymicrobial nature of periodontal disease

We have shown that AMD3100 treatment has a relatively specific effect on
disease progression when pathology is instigated solely by P. gingivalis, however,
chronic periodontal disease is more and more being characterized as a polymicrobial
disease of the host immunity. In other words, many oral pathogens or microbial
opportunists are present in the patients oral cavity and contribute to disease progression.
Knowing the inhibitory effect of AMD3100 on P. gingivalis survival, and that F.
nucleatum is not atTected by AMD3100 in the chamber model is a starting point for
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pressing on to ask what the effects of AMD31 00 treatment are on the total oral microbe
community. Are there lasting ecological effects of CXCR4 blockade? Is the population
balance shifted, and if so, in what way? These questions lead to even more fundamental
questions concerning the nature of our interaction with environmental microflora. Such
as, does CXCR4 deficiency cause a shift in the population dynamics of the oral
microbiota in mice, and with what consequence? We observed mice for sixty days, to an
approximate age of 3 months, but what about longer term effects of CXCR4 blockade? It
is difficult to believe that absence/blockade of the receptor would have no effect,
especially concerning the knowledge that certain viruses and P. gingivalis use it for
pathogenic gain.

AMD3100 periodontal treatment and its (fortuitous?) effect on other systemic
diseases?
We have demonstrated a therapeutic advantage to AMD31 00 administration on a
systemic scale, an exciting finding considering the current philosophy that periodontal
and certain systemic diseases of inflammatory or autoimmune etiology share a
relationship of bidirectional effects. As stated above, it has been shown that diabetic
patients suffer an increased prevalence and severity of periodontal disease, and that
chronic periodontitis can worsen or accelerate metabolic disease which leads to diabetes.
Periodontitis also has been shown as both a risk factor for and disease of consequence for
patients suffering rheumatoid arthritis. This, coupled with a finding regarding the benefit
of systemic AMD31 00 treatment via the same osmotic pumps used in this study on mice
with CIA (168), raises the possibility that therapy for disorders such as rheumatoid
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arthritis, diabetes and atherosclerosis could overlap. Periodontal treatment might benefit
patients by reducing risk of associated diseases not only through improved oral health but
also through pharmacological targeting so that individual patients can enjoy a maximized
benefit with minimized pharmaceutical burden.
In conclusion, systemic pharmacological blockade of CXCR4 signaling provides
protection and therapy in a P. gingivalis mediated model of chronic periodontitis by
enhancing specific clearance of the pathogen. These findings will hopefully aid in
directing development of therapeutic strategies that will not only possess relevance in a
preventative context but also provide strategies for halting periodontal disease such that a
focus can be placed eventually upon healing damage already done in afflicted patients.
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